

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/55, 9/22, 15/90, 15/85</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/10077</b> <b>(43) International Publication Date:</b> 12 March 1998 (12.03.98)
<b>(21) International Application Number:</b> PCT/US97/15941 <b>(22) International Filing Date:</b> 9 September 1997 (09.09.97)  <b>(30) Priority Data:</b> 08/814,877 9 September 1996 (09.09.96) US 08/850,880 2 May 1997 (02.05.97) US  <b>(71) Applicant:</b> WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 North Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).  <b>(72) Inventors:</b> REZNIKOFF, William, S.; 733 Lakewood Boulevard, Maple Bluff, WI 53704 (US). GORYSHIN, Igor, Yu; Apartment D, 23 University Houses, Madison, WI 53705 (US). ZHOU, Hong; Apartment 104, 5331 Brody Drive, Madison, WI 53705 (US).  <b>(74) Agent:</b> BERSON, Bennett, J.; Quarles & Brady, P.O. Box 2113, Madison, WI 53701-2113 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> SYSTEM FOR <i>IN VITRO</i> TRANSPOSITION USING MODIFIED Tn5 TRANSPOSASE  <b>(57) Abstract</b>  A system for <i>in vitro</i> transposition includes a donor DNA that includes a transposable element flanked by a pair of bacterial transposon Tn5 outside end repeat sequences, a target DNA into which the transposable element can transpose, and a modified Tn5 transposase having higher binding avidity to the outside end repeat sequences and being less likely to assume an inactive multimer form than wild type Tn5 transposase.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

SYSTEM FOR *IN VITRO* TRANSPOSITION USING MODIFIED TNS TRANSPOSASE

## CROSS-REFERENCE TO RELATED APPLICATION

10 This patent application is a continuation-in-part of a patent application entitled "System for *In Vitro* Transposition," filed March 11, 1997, for which no serial number has yet been accorded. Applicants have petitioned for a filing date of September 9, 1996 to be accorded to the parent application.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT  
Not applicable.

15

## BACKGROUND OF THE INVENTION

The present invention relates generally to the field of transposable nucleic acid and, more particularly to production and use of a modified transposase enzyme in a system for introducing genetic changes to nucleic acid.

20

Transposable genetic elements are DNA sequences, found in a wide variety of prokaryotic and eukaryotic organisms, that can move or transpose from one position to another position in a genome. *In vivo*, intra-chromosomal transpositions as well as transpositions between chromosomal and non-chromosomal genetic material are known. In several systems, transposition is known to be under the control of a transposase enzyme that is typically encoded by the transposable element. The genetic structures and transposition mechanisms of various transposable elements are summarized, for example, in "Transposable Genetic Elements" in "The Encyclopedia of Molecular Biology," Kendrew and Lawrence, Eds., Blackwell Science, Ltd., Oxford (1994), incorporated herein by reference.

25

30

*In vitro* transposition systems that utilize the particular transposable elements of bacteriophage Mu and bacterial transposon Tn10 have been described, by the research groups of

35

5 Kiyoshi Mizuuchi and Nancy Kleckner, respectively.

The bacteriophage Mu system was first described by Mizuuchi, K., "In Vitro Transposition of Bacteria Phage Mu: A Biochemical Approach to a Novel Replication Reaction," Cell:785-794 (1983) and Craigie, R. et al., "A Defined System for the DNA Strand-Transfer Reaction at the Initiation of Bacteriophage Mu Transposition: Protein and DNA Substrate Requirements," P.N.A.S. U.S.A. 82:7570-7574 (1985). The DNA donor substrate (mini-Mu) for Mu *in vitro* reaction normally requires six Mu transposase binding sites (three of about 30 bp at each end) and an enhancer sequence located about 1 kb from the left end. The donor plasmid must be supercoiled. Proteins required are Mu-encoded A and B proteins and host-encoded HU and IHF proteins. Lavoie, B.D, and G. Chaconas, "Transposition of phage Mu DNA," Curr. Topics Microbiol. Immunol. 204:83-99 (1995). The Mu-based system is disfavored for *in vitro* transposition system applications because the Mu termini are complex and sophisticated and because transposition requires additional proteins above and beyond the transposase.

The Tn10 system was described by Morisato, D. and N. Kleckner, "Tn10 Transposition and Circle Formation *in vitro*," Cell 51:101-111 (1987) and by Benjamin, H. W. and N. Kleckner, "Excision Of Tn10 from the Donor Site During Transposition Occurs By Flush Double-Strand Cleavages at the Transposon Termini," P.N.A.S. U.S.A. 89:4648-4652 (1992). The Tn10 system involves the a supercoiled circular DNA molecule carrying the transposable element (or a linear DNA molecule plus *E. coli* IHF protein). The transposable element is defined by complex 42 bp terminal sequences with IHF binding site adjacent to the inverted repeat. In fact, even longer (81 bp) ends of Tn10 were used in reported experiments. Sakai, J. et al., "Identification and Characterization of Pre-Cleavage Synaptic Complex that is an Early Intermediate in Tn10 transposition," E.M.B.O. J. 14:4374-4383 (1995). In the Tn10 system, chemical treatment of the transposase protein is essential to support active transposition. In addition, the termini of the Tn10 element limit its utility in a generalized *in vitro*

5 transposition system.

Both the Mu- and Tn10-based *in vitro* transposition systems are further limited in that they are active only on covalently closed circular, supercoiled DNA targets. What is desired is a more broadly applicable *in vitro* transposition system that  
10 utilizes shorter, more well defined termini and which is active on target DNA of any structure (linear, relaxed circular, and supercoiled circular DNA).

#### BRIEF SUMMARY OF THE INVENTION

The present invention is summarized in that an *in vitro*  
15 transposition system comprises a preparation of a suitably modified transposase of bacterial transposon Tn5, a donor DNA molecule that includes a transposable element, a target DNA molecule into which the transposable element can transpose, all provided in a suitable reaction buffer.

20 The transposable element of the donor DNA molecule is characterized as a transposable DNA sequence of interest, the DNA sequence of interest being flanked at its 5'- and 3'-ends by short repeat sequences that are acted upon *in trans* by Tn5 transposase.

25 The invention is further summarized in that the suitably modified transposase enzyme comprises two classes of differences from wild type Tn5 transposase, where each class has a separate measurable effect upon the overall transposition activity of the enzyme and where a greater effect is observed  
30 when both modifications are present. The suitably modified enzyme both (1) binds to the repeat sequences of the donor DNA with greater avidity than wild type Tn5 transposase ("class (1) mutation") and (2) is less likely than the wild type protein to assume an inactive multimeric form ("class (2) mutation"). A  
35 suitably modified Tn5 transposase of the present invention that contains both class (1) and class (2) modifications induces at least about 100-fold ( $\pm 10\%$ ) more transposition than the wild type enzyme, when tested in combination in an *in vivo* conjugation assay as described by Weinreich, M.D., "Evidence  
40 that the *cis* Preference of the Tn5 Transposase is Caused by

5 Nonproductive Multimerization," Genes and Development 8:2363-  
2374 (1994), incorporated herein by reference. Under optimal  
conditions, transposition using the modified transposase may be  
higher. A modified transposase containing only a class (1)  
10 mutation binds to the repeat sequences with sufficiently  
greater avidity than the wild type Tn5 transposase that such a  
Tn5 transposase induces about 5- to 50-fold more transposition  
than the wild type enzyme, when measured *in vivo*. A modified  
transposase containing only a class (2) mutation is  
15 sufficiently less likely than the wild type Tn5 transposase to  
assume the multimeric form that such a Tn5 transposase also  
induces about 5- to 50-fold more transposition than the wild  
type enzyme, when measured *in vivo*.

In another aspect, the invention is summarized in that a  
method for transposing the transposable element from the donor  
20 DNA into the target DNA *in vitro* includes the steps of mixing  
together the suitably modified Tn5 transposase protein, the  
donor DNA, and the target DNA in a suitable reaction buffer,  
allowing the enzyme to bind to the flanking repeat sequences of  
the donor DNA at a temperature greater than 0°C, but no higher  
25 than about 28°C, and then raising the temperature to  
physiological temperature (about 37°C) whereupon cleavage and  
strand transfer can occur.

It is an object of the present invention to provide a  
useful *in vitro* transposition system having few structural  
30 requirements and high efficiency.

It is another object of the present invention to provide a  
method that can be broadly applied in various ways, such as to  
create absolute defective mutants, to provide selective markers  
to target DNA, to provide portable regions of homology to a  
35 target DNA, to facilitate insertion of specialized DNA  
sequences into target DNA, to provide primer binding sites or  
tags for DNA sequencing, to facilitate production of genetic  
fusions for gene expression studies and protein domain mapping,  
as well as to bring together other desired combinations of DNA  
40 sequences (combinatorial genetics).

It is a feature of the present invention that the modified

5 transposase enzyme binds more tightly to DNA than does wild type Tn5 transposase.

It is an advantage of the present invention that the modified transposase facilitates *in vitro* transposition reaction rates of at least about 100-fold higher than can be achieved using wild type transposase (as measured *in vivo*). It is noted that the wild-type Tn5 transposase shows no detectable *in vitro* activity in the system of the present invention. Thus, while it is difficult to calculate an upper limit to the increase in activity, it is clear that hundreds, if not thousands, of colonies are observed when the products of *in vitro* transposition are assayed *in vivo*.

It is another advantage of the present invention that *in vitro* transposition using this system can utilize donor DNA and target DNA that is circular or linear.

It is yet another advantage of the present invention that *in vitro* transposition using this system requires no outside high energy source and no other protein other than the modified transposase.

Other objects, features, and advantages of the present invention will become apparent upon consideration of the following detailed description.

#### BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Fig. 1 depicts test plasmid pRZTL1, used herein to demonstrate transposition *in vitro* of a transposable element located between a pair of Tn5 outside end termini. Plasmid pRZTL1 is also shown and described in SEQ ID NO:3.

Fig. 2 depicts an electrophoretic analysis of plasmid pRZTL1 before and after *in vitro* transposition. Data obtained using both circular and linear plasmid substrates are shown.

Fig. 3 is an electrophoretic analysis of plasmid pRZTL1 after *in vitro* transposition, including further analysis of the molecular species obtained using circular and linear plasmid substrates.

Fig. 4 shows plasmids pRZ1496, pRZ5451 and pRZTL1, which are detailed in the specification.

5 Fig. 5 shows a plot of papillae per colony over time for various mutant OE sequences tested *in vivo* against EK54/MA56 transposase.

Fig. 6 shows a plot of papillae per colony over time for various mutant OE sequences with a smaller Y-axis than is shown  
10 in Fig. 5 tested against EK54/MA56 transposase.

Fig. 7 shows a plot of papillae per colony over time for various mutant OE sequences tested against MA56 Tn5 transposase.

15 Fig. 8 shows *in vivo* transposition using two preferred mutants, tested against MA56 and EK54/MA56 transposase.

#### DETAILED DESCRIPTION OF THE INVENTION

It will be appreciated that this technique provides a simple, *in vitro* system for introducing any transposable element from a donor DNA into a target DNA. It is generally  
20 accepted and understood that Tn5 transposition requires only a pair of OE termini, located to either side of the transposable element. These OE termini are generally thought to be 18 or 19 bases in length and are inverted repeats relative to one another. Johnson, R. C., and W. S. Reznikoff, Nature 304:280  
25 (1983), incorporated herein by reference. The Tn5 inverted repeat sequences, which are referred to as "termini" even though they need not be at the termini of the donor DNA molecule, are well known and understood.

Apart from the need to flank the desired transposable element with standard Tn5 outside end ("OE") termini, few other requirements on either the donor DNA or the target DNA are  
30 envisioned. It is thought that Tn5 has few, if any, preferences for insertion sites, so it is possible to use the system to introduce desired sequences at random into target DNA. Therefore, it is believed that this method, employing the  
35 modified transposase described herein and a simple donor DNA, is broadly applicable to introduce changes into any target DNA, without regard to its nucleotide sequence. It will, thus, be applied to many problems of interest to those skilled in the  
40 art of molecular biology.



5 In the method, the modified transposase protein is combined in a suitable reaction buffer with the donor DNA and the target DNA. A suitable reaction buffer permits the transposition reaction to occur. A preferred, but not necessarily optimized, buffer contains spermidine to condense  
10 the DNA, glutamate, and magnesium, as well as a detergent, which is preferably 3-[(3-cholamidopropyl) dimethyl-ammonio]-1-propane sulfonate ("CHAPS"). The mixture can be incubated at a temperature greater than 0°C and as high as about 28°C to facilitate binding of the enzyme to the OE termini. Under the  
15 buffer conditions used by the inventors in the Examples, a pretreatment temperature of 30°C was not adequate. A preferred temperature range is between 16°C and 28°C. A most preferred pretreatment temperature is about 20°C. Under different buffer conditions, however, it may be possible to use other below-  
20 physiological temperatures for the binding step. After a short pretreatment period of time (which has not been optimized, but which may be as little as 30 minutes or as much as 2 hours, and is typically 1 hour), the reaction mixture is diluted with 2 volumes of a suitable reaction buffer and shifted to  
25 physiological conditions for several more hours (say 2-3 hours) to permit cleavage and strand transfer to occur. A temperature of 37°C, or thereabouts, is adequate. After about 3 hours, the rate of transposition decreases markedly. The reaction can be stopped by phenol-chloroform extraction and can then be  
30 desalted by ethanol precipitation.

When the DNA has been purified using conventional purification tools, it is possible to employ simpler reaction conditions in the in vitro transposition method. DNA of sufficiently high purity can be prepared by passing the DNA  
35 preparation through a resin of the type now commonly used in the molecular biology laboratory, such as the Qiagen resin of the Qiagen plasmid purification kit (Catalog No. 12162). When such higher quality DNA is employed, CHAPS can be omitted from the reaction buffer. When CHAPS is eliminated from the  
40 reaction buffer, the reactants need not be diluted in the manner described above. Also, the low temperature incubation

5 step noted above can be eliminated in favor of a single incubation for cleavage and strand transfer at physiological conditions. A three hour incubation at 37°C is sufficient.

Following the reaction and subsequent extraction steps, transposition can be assayed by introducing the nucleic acid  
10 reaction products into suitable bacterial host cells (e.g., *E. coli* K-12 DH5α cells (recA<sup>-</sup>); commercially available from Life Technologies (Gibco-BRL)) preferably by electroporation, described by Dower et al., Nuc. Acids. Res. 16:6127 (1988), and monitoring for evidence of transposition, as is described  
15 elsewhere herein.

Those persons skilled in the art will appreciate that apart from the changes noted herein, the transposition reaction can proceed under much the same conditions as would be found in an *in vivo* reaction. Yet, the modified transposase described  
20 herein so increases the level of transposition activity that it is now possible to carry out this reaction *in vitro* where this has not previously been possible. The rates of reaction are even greater when the modified transposase is coupled with an optimized buffer and temperature conditions noted herein.

25 In another aspect, the present invention is a preparation of a modified Tn5 transposase enzyme that differs from wild type Tn5 transposase in that it (1) binds to the repeat sequences of the donor DNA with greater avidity than wild type Tn5 transposase and (2) is less likely than the wild type  
30 protein to assume an inactive multimeric form. An enzyme having these requirements can be obtained from a bacterial host cell containing an expressible gene for the modified enzyme that is under the control of a promoter active in the host cell. Genetic material that encodes the modified Tn5  
35 transposase can be introduced (e.g., by electroporation) into suitable bacterial host cells capable of supporting expression of the genetic material. Known methods for overproducing and preparing other Tn5 transposase mutants are suitably employed. For example, Weinreich, M. D., et al., *supra*, describes a  
40 suitable method for overproducing a Tn5 transposase. A second method for purifying Tn5 transposase was described in de la

5 Cruz, N. B., et al., "Characterization of the Tn5 Transposase  
and Inhibitor Proteins: A Model for the Inhibition of  
Transposition," J. Bact. 175:6932-6938 (1993), also  
incorporated herein by reference. It is noted that induction  
can be carried out at temperatures below 37°C, which is the  
10 temperature used by de la Cruz, et al. Temperatures at least in  
the range of 33 to 37°C are suitable. The inventors have  
determined that the method for preparing the modified  
transposase of the present invention is not critical to success  
of the method, as various preparation strategies have been used  
15 with equal success.

Alternatively, the protein can be chemically synthesized,  
in a manner known to the art, using the amino acid sequence  
attached hereto as SEQ ID NO:2 as a guide. It is also possible  
to prepare a genetic construct that encodes the modified  
20 protein (and associated transcription and translation signals)  
by using standard recombinant DNA methods familiar to molecular  
biologists. The genetic material useful for preparing such  
constructs can be obtained from existing Tn5 constructs, or can  
be prepared using known methods for introducing mutations into  
25 genetic material (e.g., random mutagenesis PCR or site-directed  
mutagenesis) or some combination of both methods. The genetic  
sequence that encodes the protein shown in SEQ ID NO:2 is set  
forth in SEQ ID NO:1.

The nucleic acid and amino acid sequence of wild type Tn5  
30 transposase are known and published. N.C.B.I. Accession Number  
U00004 L19385, incorporated herein by reference.

In a preferred embodiment, the improved avidity of the  
modified transposase for the repeat sequences for OE termini  
(class (1) mutation) can be achieved by providing a lysine  
35 residue at amino acid 54, which is glutamic acid in wild type  
Tn5 transposase. The mutation strongly alters the preference  
of the transposase for OE termini, as opposed to inside end  
("IE") termini. The higher binding of this mutation, known as  
EK54, to OE termini results in a transposition rate that is  
40 about 10-fold higher than is seen with wild type transposase.  
A similar change at position 54 to valine (mutant EV54) also

5 results in somewhat increased binding/transposition for OE  
termini, as does a threonine-to-proline change at position 47  
(mutant TP47; about 10-fold higher). It is believed that  
other, comparable transposase mutations (in one or more amino  
acids) that increase binding avidity for OE termini may also be  
10 obtained which would function as well or better in the *in vitro*  
assay described herein.

One of ordinary skill will also appreciate that changes to  
the nucleotide sequences of the short repeat sequences of the  
donor DNA may coordinate with other mutation(s) in or near the  
15 binding region of the transposase enzyme to achieve the same  
increased binding effect, and the resulting 5- to 50-fold  
increase in transposition rate. Thus, while the applicants  
have exemplified one case of a mutation that improves binding  
of the exemplified transposase, it will be understood that  
20 other mutations in the transposase, or in the short repeat  
sequences, or in both, will also yield transposases that fall  
within the scope and spirit of the present invention. A  
suitable method for determining the relative avidity for Tn5 OE  
termini has been published by Jilk, R. A., et al., "The  
25 Organization of the Outside end of Transposon Tn5," J. Bact.  
178:1671-79 (1996).

The transposase of the present invention is also less  
likely than the wild type protein to assume an inactive  
multimeric form. In the preferred embodiment, that class (2)  
30 mutation from wild type can be achieved by modifying amino acid  
372 (leucine) of wild type Tn5 transposase to a proline (and,  
likewise by modifying the corresponding DNA to encode proline).  
This mutation, referred to as LP372, has previously been  
characterized as a mutation in the dimerization region of the  
35 transposase. Weinreich, et al., *supra*. It was noted by  
Weinreich et al. that this mutation at position 372 maps to a  
region shown previously to be critical for interaction with an  
inhibitor of Tn5 transposition. The inhibitor is a protein  
encoded by the same gene that encodes the transposase, but  
40 which is truncated at the N-terminal end of the protein,  
relative to the transposase. The approach of Weinreich et al.

5 for determining the extent to which multimers are formed is suitable for determining whether a mutation falls within the scope of this element.

10 It is thought that when wild type Tn5 transposase multimerizes, its activity *in trans* is reduced. Presumably, a mutation in the dimerization region reduces or prevents multimerization, thereby reducing inhibitory activity and leading to levels of transposition 5- to 50-fold higher than are seen with the wild type transposase. The LP372 mutation achieves about 10-fold higher transposition levels than wild type. Likewise, other mutations (including mutations at a one or more amino acid) that reduce the ability of the transposase to multimerize would also function in the same manner as the single mutation at position 372, and would also be suitable in a transposase of the present invention. It may also be possible to reduce the ability of a Tn5 transposase to multimerize without altering the wild type sequence in the so-called dimerization region, for example by adding into the system another protein or non-protein agent that blocks the dimerization site. Alternatively, the dimerization region could be removed entirely from the transposase protein.

25 As was noted above, the inhibitor protein, encoded in partially overlapping sequence with the transposase, can interfere with transposase activity. As such, it is desired that the amount of inhibitor protein be reduced over the amount observed in wild type *in vivo*. For the present assay, the transposase is used in purified form, and it may be possible to separate the transposase from the inhibitor (for example, according to differences in size) before use. However, it is also possible to genetically eliminate the possibility of having any contaminating inhibitor protein present by removing its start codon from the gene that encodes the transposase.

35 An AUG in the wild type Tn5 transposase gene that encodes methionine at transposase amino acid 56 is the first codon of the inhibitor protein. However, it has already been shown that replacement of the methionine at position 56 has no apparent effect upon the transposase activity, but at the same time

5 prevents translation of the inhibitor protein, thus resulting  
in a somewhat higher transposition rate. Weigand, T. W. and W.  
S. Reznikoff, "Characterization of Two Hypertransposing Tn5  
Mutants," J. Bact. 174:1229-1239 (1992), incorporated herein by  
10 reference. In particular, the present inventors have replaced  
the methionine with an alanine in the preferred embodiment (and  
have replaced the methionine-encoding AUG codon with an  
alanine-encoding GCC). A preferred transposase of the present  
invention therefore includes an amino acid other than  
15 methionine at amino acid position 56, although this change can  
be considered merely technically advantageous (since it ensures  
the absence of the inhibitor from the *in vitro* system) and not  
essential to the invention (since other means can be used to  
eliminate the inhibitor protein from the *in vitro* system).

The most preferred transposase amino acid sequence known  
20 to the inventors differs from the wild type at amino acid  
positions 54, 56, and 372. The mutations at positions 54 and  
372 separately contribute approximately a 10-fold increase to  
the rate of transposition reaction *in vivo*. When the mutations  
are combined using standard recombinant techniques into a  
25 single molecule containing both classes of mutations, reaction  
rates of at least about 100-fold higher than can be achieved  
using wild type transposase are observed when the products of  
the *in vitro* system are tested *in vivo*. The mutation at  
position 56 does not directly affect the transposase activity.

30 Other mutants from wild type that are contemplated to be  
likely to contribute to high transposase activity *in vitro*  
include, but are not limited to glutaminic acid-to-lysine at  
position 110, and glutamic acid to lysine at position 345.

It is, of course, understood that other changes apart from  
35 these noted positions can be made to the modified transposase  
(or to a construct encoding the modified transposase) without  
adversely affecting the transposase activity. For example, it  
is well understood that a construct encoding such a transposase  
could include changes in the third position of codons such that  
40 the encoded amino acid does not differ from that described  
herein. In addition, certain codon changes have little or no

5 functional effect upon the transposition activity of the  
encoded protein. Finally, other changes may be introduced  
which provide yet higher transposition activity in the encoded  
protein. It is also specifically envisioned that combinations  
10 of mutations can be combined to encode a modified transposase  
having even higher transposition activity than has been  
exemplified herein. All of these changes are within the scope  
of the present invention. It is noted, however, that a  
modified transposase containing the EK110 and EK345 mutations  
(both described by Weigand and Reznikoff, *supra*, had lower  
15 transposase activity than a transposase containing either  
mutation alone.

After the enzyme is prepared and purified, as described  
*supra*, it can be used in the *in vitro* transposition reaction  
described above to introduce any desired transposable element  
20 from a donor DNA into a target DNA. The donor DNA can be  
circular or can be linear. If the donor DNA is linear, it is  
preferred that the repeat sequences flanking the transposable  
element should not be at the termini of the linear fragment but  
should rather include some DNA upstream and downstream from the  
25 region flanked by the repeat sequences.

As was noted above, Tn5 transposition requires a pair of  
eighteen or nineteen base long termini. The wild type Tn5  
outside end (OE) sequence (5'-CTGACTCTTATACACAAGT-3') (SEQ ID  
NO: 7) has been described. It has been discovered that a  
30 transposase-catalyzed *in vitro* transposition frequency at least  
as high as that of wild type OE is achieved if the termini in a  
construct include bases ATA at positions 10, 11, and 12,  
respectively, as well as the nucleotides in common between wild  
type OE and IE (e.g., at positions 1-3, 5-9, 13, 14, 16, and  
35 optionally 19). The nucleotides at positions 4, 15, 17, and 18  
can correspond to the nucleotides found at those positions in  
either wild type OE or wild type IE. It is noted that the  
transposition frequency can be enhanced over that of wild type  
OE if the nucleotide at position 4 is a T. The importance of  
40 these particular bases to transposition frequency has not  
previously been identified.

5           It is noted that these changes are not intended to  
encompass every desirable modification to OE. As is described  
elsewhere herein, these attributes of acceptable termini  
modifications were identified by screening mutants having  
10           randomized differences between IE and OE termini. While the  
presence in the termini of certain nucleotides is shown herein  
to be advantageous, other desirable terminal sequences may yet  
be obtained by screening a larger array of degenerate mutants  
that include changes at positions other than those tested  
15           herein as well as mutants containing nucleotides not tested in  
the described screening. In addition, it is clear to one  
skilled in the art that if a different transposase is used, it  
may still be possible to select other variant termini, more  
compatible with that particular transposase.

20           Among the mutants shown to be desirable and within the  
scope of the invention are two hyperactive mutant OE sequences  
that were identified *in vivo*. Although presented here as  
single stranded sequences, in fact, the wild type and mutant OE  
sequences include complementary second strands. The first  
hyperactive mutant, 5'-CTGTCTCTTATACACATCT-3' (SEQ ID NO: 8),  
25           differs from the wild type OE sequence at positions 4, 17, and  
18, counting from the 5' end, but retains ATA at positions 10-  
12. The second, 5'-CTGTCTCTTATACAGATCT-3' (SEQ ID NO: 9),  
differs from the wild type OE sequence at positions 4, 15, 17,  
and 18, but also retains ATA at positions 10-12. These two  
30           hyperactive mutant OE sequences differ from one another only at  
position 15, where either G or C is present. OE-like activity  
(or higher activity) is observed in a mutant sequence when it  
contains ATA at positions 10, 11 and 12. It may be possible to  
reduce the length of the OE sequence from 19 to 18 nucleotide  
35           pairs with little or no effect.

40           When one of the identified hyperactive mutant OE sequences  
flanks a substrate DNA, the *in vivo* transposition frequency of  
EK54/MA56 transposase is increased approximately 40-60 fold  
over the frequency that is observed when wild type OE termini  
flank the transposable DNA. The EK54/MA56 transposase is  
already known to have an *in vivo* transposition frequency



5 approximately an 8-10 fold higher than wild type transposase, using wild type OE termini. Tn5 transposase having the EK54/MA56 mutation is known to bind with greater avidity to OE and with lesser avidity to the Tn5 inside ends (IE) than wild type transposase.

10 A suitable mutant terminus in a construct for use in the assays of the present invention is characterized biologically as yielding more papillae per colony in a comparable time, say 68 hours, than is observed in colonies harboring wild type OE in a comparable plasmid. Wild type OE can yield about 100  
15 papillae per colony when measured 68 hours after plating in a papillation assay using EK54/MA56 transposase, as is described elsewhere herein. A preferred mutant would yield between about 200 and 3000 papillae per colony, and a more preferred mutant between about 1000 and 3000 papillae per colony, when measured  
20 in the same assay and time frame. A most preferred mutant would yield between about 2000 and 3000 papillae per colony when assayed under the same conditions. Papillation levels may be even greater than 3000 per colony, although it is difficult to quantitate at such levels.

25 Transposition frequency is also substantially enhanced in the *in vitro* transposition assay of the present invention when substrate DNA is flanked by a preferred mutant OE sequence and a most preferred mutant transposase (comprising EK54/MA56/LP372 mutations) is used. Under those conditions, essentially all of  
30 the substrate DNA is converted into transposition products.

The rate of *in vitro* transposition observed using the hyperactive termini is sufficiently high that, in the experience of the inventors, there is no need to select for  
35 transposition events. All colonies selected at random after transformation for further study have shown evidence of transposition events.

This advance can represent a significant savings in time and laboratory effort. For example, it is particularly advantageous to be able to improve *in vitro* transposition  
40 frequency by modifying DNA rather than by modifying the transposase because as transposase activity increases in host

5 cells, there is an increased likelihood that cells containing  
the transposase are killed during growth as a result of  
aberrant DNA transpositions. In contrast, DNA of interest  
containing the modified OE termini can be grown in sources  
completely separate from the transposase, thus not putting the  
10 host cells at risk.

Without intending to limit the scope of this aspect of  
this invention, it is apparent that the tested hyperactive  
termini do not bind with greater avidity to the transposase  
than do wild type OE termini. Thus, the higher transposition  
15 frequency brought about by the hyperactive termini is not due  
to enhanced binding to transposase.

The transposable element between the termini can include  
any desired nucleotide sequence. The length of the  
transposable element between the termini should be at least  
20 about 50 base pairs, although smaller inserts may work. No  
upper limit to the insert size is known. However, it is known  
that a donor DNA portion of about 300 nucleotides in length can  
function well. By way of non-limiting examples, the  
transposable element can include a coding region that encodes a  
25 detectable or selectable protein, with or without associated  
regulatory elements such as promoter, terminator, or the like.

If the element includes such a detectable or selectable  
coding region without a promoter, it will be possible to  
identify and map promoters in the target DNA that are uncovered  
30 by transposition of the coding region into a position  
downstream thereof, followed by analysis of the nucleic acid  
sequences upstream from the transposition site.

Likewise, the element can include a primer binding site  
that can be transposed into the target DNA, to facilitate  
35 sequencing methods or other methods that rely upon the use of  
primers distributed throughout the target genetic material.  
Similarly, the method can be used to introduce a desired  
restriction enzyme site or polylinker, or a site suitable for  
another type of recombination, such as a cre-lox, into the  
40 target.

The invention can be better understood upon consideration

5 of the following examples which are intended to be exemplary and not limiting on the invention.

#### EXAMPLES

10 To obtain the transposase modified at position 54, the first third of the coding region from an existing DNA clone that encodes the Tn5 transposase but not the inhibitor protein (MA56) was mutagenized according to known methods and DNA fragments containing the mutagenized portion were cloned to produce a library of plasmid clones containing a full length transposase gene. The clones making up the library were  
15 transformed into *E. coli* K-12 strain MDW320 bacteria which were plated and grown into colonies. Transposable elements provided in the bacteria on a separate plasmid contained a defective lacZ gene. The separate plasmid, pOXgen386, was described by Weinreich, M. et al., "A functional analysis of the Tn5  
20 Transposase: Identification of Domains Required for DNA Binding and Dimerization," J. Mol. Biol. 241:166-177 (1993), incorporated herein by reference. Colonies having elevated transposase activity were selected by screening for blue (LacZ) spots in white colonies grown in the presence of X-gal. This  
25 papillation assay was described by Weinreich, et al. (1993), supra. The 5'-most third of Tn5 transposase genes from such colonies were sequenced to determine whether a mutation was responsible for the increase in transposase activity. It was determined that a mutation at position 54 to lysine (K)  
30 correlated well with the increase in transposase activity. Plasmid pRZ5412-EK54 contains lysine at position 54 as well as the described alanine at position 56.

The fragment containing the LP372 mutation was isolated from pRZ4870 (Weinreich et al (1994)) using restriction enzymes  
35 NheI and BglII, and were ligated into NheI-BglII cut pRZ5412-EK54 to form a recombinant gene having the mutations at positions 54, 56 and 372, as described herein and shown in SEQ ID NO:1. The gene was tested and shown to have at least about a one hundred fold increase in activity relative to wild type  
40 Tn5 transposase. Each of the mutants at positions 54 and 372

5 alone had about a 10-fold increase in transposase activity.

The modified transposase protein encoded by the triple-mutant recombinant gene was transferred into commercial T7 expression vector pET-21D (commercially available from Novagen, Madison, WI) by inserting a BspHI/SalI fragment into NhoI/XhoI  
10 fragment of the pET-21D vector. This cloning puts the modified transposase gene under the control of the T7 promoter, rather than the natural promoter of the transposase gene. The gene product was overproduced in BL21(DE3)pLyss bacterial host cells, which do not contain the binding site for the enzyme, by  
15 specific induction in a fermentation process after cell growth is complete. (See, Studier, F. W., et al., "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes," Methods Enzymol. 185:60-89 (1990)). The transposase was partially purified using the method of de la Cruz, modified by inducing  
20 overproduction at 33 or 37°C. After purification, the enzyme preparation was stored at -70°C in a storage buffer (10% glycerol, 0.7M NaCl, 20 mM Tris-HCl, pH 7.5, 0.1% Triton-X100 and 10 mM CHAPS) until use. This storage buffer is to be considered exemplary and not optimized.

25 A single plasmid (pRZTL1, Fig. 1) was constructed to serve as both donor and target DNA in this Example. The complete sequence of the pRZTL1 plasmid DNA is shown and described in SEQ ID NO:3. Plasmid pRZTL1 contains two Tn5 19 base pair OE termini in inverted orientation to each other. Immediately  
30 adjacent to one OE sequence is a gene that would encode tetracycline resistance, but for the lack of an upstream promoter. However, the gene is expressed if the tetracycline resistance gene is placed downstream of a transcribed region (e.g., under the control of the promoter that promotes  
35 transcription of the chloramphenicol resistance gene also present on pRZTL1). Thus, the test plasmid pRZTL1 can be assayed *in vivo* after the *in vitro* reaction to confirm that transposition has occurred. The plasmid pRZTL1 also includes an origin of replication in the transposable element, which  
40 ensures that all transposition products are plasmids that can replicate after introduction in host cells.

5           The following components were used in typical 20 $\mu$ l in vitro transposition reactions:

Modified transposase: 2  $\mu$ l (approximately 0.1  $\mu$ g enzyme/ $\mu$ l) in storage buffer (10% glycerol, 0.7M NaCl, 20 mM Tris-HCl, pH 7.5, 0.1% Triton-X100 and 10 mM CHAPS)

10           Donor/Target DNA: 18  $\mu$ l (approximately 1-2  $\mu$ g) in reaction buffer (at final reaction concentrations of 0.1 M potassium glutamate, 25 mM Tris acetate, pH 7.5, 10 mM Mg<sup>2+</sup>-acetate, 50  $\mu$ g/ml BSA, 0.5 mM  $\beta$ -mercaptoethanol, 2 mM spermidine, 100  $\mu$ g/ml tRNA).

15           At 20°C, the transposase was combined with pRZTL1 DNA for about 60 minutes. Then, the reaction volume was increased by adding two volumes of reaction buffer and the temperature was raised to 37°C for 2-3 hours whereupon cleavage and strand transfer occurred.

20           Efficient in vitro transposition was shown to have occurred by in vivo and by in vitro methods. In vivo, many tetracycline-resistant colonies were observed after transferring the nucleic acid product of the reaction into DH5 $\alpha$  bacterial cells. As noted, tetracycline resistance can only  
25           arise in this system if the transposable element is transposed downstream from an active promoter elsewhere on the plasmid. A typical transposition frequency was 0.1% of cells that received plasmid DNA, as determined by counting chloramphenicol  
30           resistant colonies. However, this number underestimates the total transposition event frequency because the detection system limits the target to 1/16 of the total.

35           Moreover, in vitro electrophoretic (1% agarose) and DNA sequencing analyses of DNA isolated from purified colonies revealed products of true transposition events, including both intramolecular and intermolecular events. Results of typical reactions using circular plasmid pRZTL1 substrates are shown in Lanes 4 & 5. Lane 6 of Fig. 2 shows the results obtained using linear plasmid pRZTL1 substrates.

5       The bands were revealed on 1% agarose gels by staining  
with SYBR Green (FMC BioProducts) and were scanned on a  
Fluorimager SI (Molecular Dynamics). In Figure 2, lane 1 shows  
relaxed circle, linear, and closed circle versions of pRZTL1.  
Lanes 2 and 3 show intramolecular and intermolecular  
10       transposition products after *in vitro* transposition of pRZTL1,  
respectively. The products were purified from electroporated  
DH5 $\alpha$  cells and were proven by size and sequence analysis to be  
genuine transposition products. Lanes 4 and 5 represent  
products of two independent *in vitro* reactions using a mixture  
15       of closed and relaxed circular test plasmid substrates. In  
lane 6, linear pRZTL1 (XhoI-cut) was the reaction substrate.  
Lane 7 includes a BstEII digest of lambda DNA as a molecular  
weight standard.

20       Fig. 3 reproduces lanes 4, 5, and 6 of Fig. 2 and shows an  
analysis of various products, based upon secondary restriction  
digest experiments and re-electroporation and DNA sequencing.  
The released donor DNA corresponds to the fragment of pRZTL1  
that contains the kanamycin resistance gene between the two OE  
sequences, or, in the case of the linear substrate, the OE-XhoI  
25       fragment. Intermolecular transposition products can be seen  
only as relaxed DNA circles. Intramolecular transposition  
products are seen as a ladder, which results from conversion of  
the initial superhelicity of the substrate into DNA knots. The  
reaction is efficient enough to achieve double transposition  
30       events that are a combination of inter- and intramolecular  
events.

35       A preliminary investigation was made into the nature of  
the termini involved in a transposition reaction. Wild type  
Tn5 OE and IE sequences were compared and an effort was  
undertaken to randomize the nucleotides at each of the seven  
positions of difference. A population of oligonucleotides  
degenerate at each position of difference was created. Thus,  
individual oligonucleotides in the population randomly included  
either the nucleotide of the wild type OE or the wild type IE  
40       sequence. In this scheme, 2<sup>7</sup> (128) distinct oligonucleotides  
were synthesized using conventional tools. These

5 oligonucleotides having sequence characteristics of both OE and  
 IE are referred to herein as OE/IE-like sequences. To avoid  
 nomenclature issues that arise because the oligonucleotides are  
 intermediate between OE and IE wild type sequences, the  
 applicants herein note that selected oligonucleotide sequences  
 10 are compared to the wild type OE rather than to wild type IE,  
 unless specifically noted. It will be appreciated by one  
 skilled in the art that if IE is selected as the reference  
 point, the differences are identical but are identified  
 differently.

15 The following depicts the positions (x) that were varied  
 in this mutant production scheme. WT OE is shown also at SEQ  
 ID NO: 7, WT IE at SEQ ID NO: 10.

5'-CTGACTCTTATACACAAGT-3' (WT OE)  
           x      xxx  x xx      (positions of difference)  
 20 5'-CTGTCTCTTGATCAGATCT-3' (WT IE)

In addition to the degenerate OE/IE-like sequences, the  
 37- base long synthetic oligonucleotides also included terminal  
*Sph*I and *Kpn*I restriction enzyme recognition and cleavage sites  
 for convenient cloning of the degenerate oligonucleotides into  
 25 plasmid vectors. Thus, a library of randomized termini was  
 created from population of 2<sup>7</sup> (128) types of degenerate  
 oligonucleotides.

Fig. 4 shows pRZ1496, the complete sequence of which is  
 presented as SEQ ID NO:11. The following features are noted in  
 30 the sequence:

<u>Feature</u>	<u>Position</u>
WT OE	94-112
LacZ coding	135-3137
LacY coding	3199-4486
35 LacA coding	4553-6295
tet <sup>r</sup> coding	6669-9442
transposase coding	10683-12111 (Comp. Strand)
Cassette IE	12184-12225
colE1 sequence	127732-19182

40 The IE cassette shown in Fig. 4 was excised using *Sph*I and  
*Kpn*I and was replaced, using standard cleavage and ligation  
 methods, by the synthetic termini cassettes comprising OE/IE-

5 like portions. Between the fixed wild type OE sequence and the  
OE/IE-like cloned sequence, plasmid pRZ1496 comprises a gene  
whose activity can be detected, namely LacZYA, as well as a  
selectable marker gene, tet<sup>r</sup>. The LacZ gene is defective in  
10 that it lacks suitable transcription and translation initiation  
signals. The LacZ gene is transcribed and translated only when  
it is transposed into a position downstream from such signals.

The resulting clones were transformed using  
electroporation into dam<sup>-</sup>, LacZ<sup>-</sup> bacterial cells, in this case  
JCM101/pOXgen cells which were grown at 37°C in LB medium under  
15 standard conditions. A dam<sup>-</sup> strain is preferred because dam  
methylation can inhibit IE utilization and wild type IE  
sequences include two dam methylation sites. A dam<sup>-</sup> strain  
eliminates dam methylation as a consideration in assessing  
transposition activity. The Tet<sup>r</sup> cells selected were LacZ<sup>-</sup>;  
20 transposition-activated Lac expression was readily detectable  
against a negative background. pOXgen is a non-essential F  
factor derivative that need not be provided in the host cells.

In some experiments, the EK54/MA56 transposase was encoded  
directly by the transformed pRZ1496 plasmid. In other  
25 experiments, the pRZ1496 plasmid was modified by deleting a  
unique HindIII/EagI fragment (nucleotides 9112-12083) from the  
plasmid (see Fig. 4) to prevent transposase production. In the  
latter experiments, the host cells were co-transformed with the  
HindIII/EagI-deleted plasmid, termed pRZ5451 (Fig. 4), and with  
30 an EK54/MA56 transposase-encoding chloramphenicol-resistant  
plasmid. In some experiments, a comparable plasmid encoding a  
wild type Tn5 transposase was used for comparison.

Transposition frequency was assessed by a papillation  
assay that measured the number of blue spots (Lac producing  
35 cells or "papillae") in an otherwise white colony. Transformed  
cells were plated (approx. 50 colonies per plate) on Glucose  
minimal Miller medium (Miller, J., Experiments in Molecular  
Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY  
(1972)) containing 0.3% casamino acids, 5-bromo-4-chloro-3-  
40 indolyl-β-D-galactoside (40 μg/ml) and phenyl-β-D-galactoside  
(0.05%). The medium contained tetracycline (15 μg/ml) and,



5 where needed, chloramphenicol (20  $\mu$ g/ml). Colonies that survived the selection were evaluated for transposition frequency *in vivo*. Although colonies exhibiting superior papillation were readily apparent to the naked eye, the number of blue spots per colony were determined over a period of  
10 several days (approximately 90 hours post-plating).

To show that the high-papillation phenotype was conferred by the end mutations in the plasmids, colonies were re-streaked if they appeared to have papillation levels higher than was observed when wild type IE was included on the plasmid.  
15 Colonies picked from the streaked culture plates were themselves picked and cultured. DNA was obtained and purified from the cultured cells, using standard protocols, and was transformed again into "clean" JCM101/pOXgen cells. Papillation levels were again compared with wild type IE-  
20 containing plasmids in the above-noted assays, and consistent results were observed.

To obtain DNA for sequencing of the inserted oligonucleotide, cultures were grown from white portions of 117 hyperpapillating colonies, and DNA was prepared from each  
25 colony using standard DNA miniprep methods. The DNA sequence of the OE/IE-like portion of 117 clones was determined (42 from transformations using pRZ1496 as the cloning vehicle; 75 from transformations using pRZ5451 as the cloning vehicle). Only 29 unique mutants were observed. Many mutants were isolated  
30 multiple times. All mutants that showed the highest papillation frequencies contain OE-derived bases at positions 10, 11, and 12. When the OE-like bases at these positions were maintained, it was impossible to measure the effect on transposition of other changes, since the papillation level was  
35 already extremely high.

One thousand five hundred seventy five colonies were screened as described above. The likelihood that all 128 possible mutant sequences were screened was greater than 95%. Thus, it is unlikely that other termini that contribute to a  
40 greater transformation frequency will be obtained using the tested transposase.

TABLE I.  
trans papillation level of hybrid end sequences with EK54 Tnp

mutant	position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	papillation level <sup>a</sup>	# of times isolated <sup>b</sup>		
IE		c	t	g	T	c	t	c	t	t	G	A	T	A	T	c	a	G	A	T	C	t	VL	0
OE					A						A	T	A	A		C		A	A	G	M	5		
1											A	T	A	A		C					H	2		
2											A	T	A	A							H	3		
3											A	T	A	A				A			H	5		
4											A	T	A	A				A			H	4		
5											A	T	A	A					G		H	6		
6											A	T	A	A				A	G		H	6		
7											A	T	A	A				A	G		H	4		
8											A	T	A	A					G		M	7		
9					A						A	T	A	A							M	3		
10					A						A	T	A	A		C					M	2		
11					A						A	T	A	A				A			M	1		
12					A						A	T	A	A					G		M	0		
13					A						A	T	A	A				A			M	0		
14					A						A	T	A	A					G		M	4		
15					A						A	T	A	A				A	G		M	4		
16											A	T	A	A				A			L	2		
17											A	T	A	A				A	G		L	1		
18											A	T	A	A				A	G		L	2		
19											A	T	A	A				A	G		L	1		
20											A	T	A	A				A	G		L	1		
21											A	T	A	A				A	G		L	1		

All hybrid end sequences isolated on pRZ5451 that papillate more frequently than wt IE, when the EK54 Tnp is expressed from pFMA187, are listed. <sup>a</sup>trans papillation levels of wt IE, wt OE and hybrid end sequences are classified as follows: VL-very low, L-low, M-medium, and H-high. Although mutants 12 and 13 were not found in this experiment, they were found in cis papillation screening (Table II).

TABLE II.  
cis papillation level of hybrid end sequences with EK54 Tnp

mutant	position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	papillation level <sup>a</sup>	# of times isolated <sup>b</sup>	
IE		c	t	g	T	c	t	c	t	t	G	A	T	A	T	c	a	G	A	T	C	t	L
OE					A						A	T	A	A								H	2
1											A	T	A	A								H	2
2											A	T	A	A								H	0
3											A	T	A	A								H	1
4											A	T	A	A								H	1
5											A	T	A	A								H	1
6											A	T	A	A								H	2
7											A	T	A	A								H	3
8											A	T	A	A								H	1
9											A	T	A	A								H	1
10											A	T	A	A								H	0
11											A	T	A	A								H	2
12											A	T	A	A								MH	3
13											A	T	A	A								MH	1
14											A	T	A	A								H	0
15											A	T	A	A								H	2
16											A	T	A	A								M	1
17											A	T	A	A								M	1
18											A	T	A	A								M	2
19											A	T	A	A								M	2
20											A	T	A	A								M	1
21											A	T	A	A								M	4
22											A	T	A	A								M	1
23											A	T	A	A								M	1
24											A	T	A	A								M	1
25											A	T	A	A								M	1
26											A	T	A	A								M	1
27											A	T	A	A								M	2

All hybrid end sequences isolated on pR21496 that papillate more frequently than wt IE, when the EK54 Tnp is expressed from the same plasmid, are listed. <sup>a</sup>cis papillation levels of wt IE, wt OE and hybrid end sequences are classified as follows: L-low, M-medium, MH-medium high, and H-high. <sup>b</sup>Although mutants 2, 10 and 14 were not found in this experiment, they were found in trans papillation screening (Table I).

5           Tables I and II report the qualitative papillation level  
of mutant constructs carrying the indicated hybrid end  
sequences or the wild type OE or IE end sequences. In the  
tables, the sequence at each position of the terminus  
corresponds to wild type IE unless otherwise noted. The  
10       applicants intend that, while the sequences are presented in  
shorthand notation, one of ordinary skill can readily determine  
the complete 19 base pair sequence of every presented mutant,  
and this specification is to be read to include all such  
complete sequences. Table I includes data from trials where  
15       the EK54 transposase was provided *in trans*; Table II, from  
those trials where the EK54 transposase was provided *in cis*.  
Although a transposase provided *in cis* is more active in  
absolute terms than a transposase provided *in trans*, the *cis* or  
*trans* source of the transposase does not alter the relative *in*  
20       *vivo* transposition frequencies of the tested termini.

Tables I and II show that every mutant that retains ATA at  
positions 10, 11, and 12, respectively, had an activity  
comparable to, or higher than, wild type OE, regardless of  
whether the wild type OE activity was medium (Table I, *trans*)  
25       or high (Table II, *cis*). Moreover, whenever that three-base  
sequence in a mutant was not ATA, the mutant exhibited lower  
papillation activity than wild type OE. It was also noted that  
papillation is at least comparable to, and tends to be  
significantly higher than, wild type OE when position 4 is a T.

30       Quantitative analysis of papillation levels was difficult,  
beyond the comparative levels shown (very low, low, medium,  
medium high, and high). However, one skilled in the art can  
readily note the papillation level of OE and can recognize  
those colonies having comparable or higher levels. It is  
35       helpful to observe the papillae with magnification.

The number of observed papillae increased over time, as is  
shown in Figs 5 - 7 which roughly quantitate the papillation  
observed in cells transformed separately with 9 clones  
containing either distinct synthetic termini cassettes or wild  
40       type OE or IE termini. In these 3 figures, each mutant is  
identified by its differences from the wild type IE sequence.

5 Note that, among the tested mutants, only mutant 10A/11T/12A  
had a higher transposition papillation level than wild type OE.  
That mutant, which would be called mutant 4/15/17/18 when OE is  
the reference sequence) was the only mutant of those shown in  
Figs. 5-7 that retained the nucleotides ATA at positions 10,  
10 11, and 12. Figs. 5 (y-axis: 0 - 1500 papillae) and 6 (y-axis:  
0 - 250 papillae) show papillation using various mutants plus  
IE and OE controls and the EK54/MA56 enzyme. Fig. 7 (y-axis: 0  
- 250 papillae), shows papillation when the same mutant  
sequences were tested against the wild type (more properly,  
15 MA56) transposase. The 10A/11T/12A mutant (SEQ ID NO: 9)  
yielded significantly more papillae (approximately 3000) in a  
shorter time (68 hours) with ED54/MA56 transposase than was  
observed even after 90 hours with the WT OE (approximately  
1500). A single OE-like nucleotide at position 15 on an IE-  
20 like background also increased papillation frequency.

In vivo transposition frequency was also quantitated in a  
tetracycline-resistance assay using two sequences having high  
levels of hyperpapillation. These sequences were 5'-  
CTGTCTCTTATACACATCT-3' (SEQ ID NO: 8), which differs from the  
25 wild type OE sequence at positions 4, 17, and 18, counting from  
the 5' end, and 5'-CTGTCTCTTATACAGATCT-3' (SEQ ID NO: 9), which  
differs from the wild type OE at positions 4, 15, 17, and 18.  
These sequences are considered the preferred mutant termini in  
an assay using a transposase that contains EK54/MA56 or a  
30 transposase that contains MA56. Each sequence was separately  
engineered into pRZTL1 in place of the plasmid's two wild type  
OE sequences. A PCR-amplified fragment containing the desired  
ends flanking the kanamycin resistance gene was readily cloned  
into the large HindIII fragment of pRZTL1. The resulting  
35 plasmids are identical to pRZTL1 except at the indicated  
termini. For comparison, pRZTL1 and a derivative of pRZTL1  
containing two wild type IE sequences were also tested. In the  
assay, JCM101/pOXgen cells were co-transformed with a test  
plasmid (pRZTL1 or derivative) and a high copy number amp<sup>r</sup>  
40 plasmid that encoded either the EK54/MA56 transposase or wild  
type (MA56) transposase. The host cells become tetracycline

5 resistant only when a transposition event brings the Tet<sup>r</sup> gene  
into downstream proximity with a suitable transcriptional  
promoter elsewhere on a plasmid or on the chromosome. The  
total number of cells that received the test plasmids was  
determined by counting chloramphenicol resistant, ampicillin  
10 resistant colonies. Transposition frequency was calculated by  
taking the ratio of tet<sup>r</sup>/cam<sup>r</sup>amp<sup>r</sup> colonies. Approximately 40 to  
60 fold increase over wild type OE in *in vivo* transposition was  
observed when using either of the mutant termini and EK54/MA56  
transposase. Of the two preferred mutant termini, the one  
15 containing mutations at three positions relative to the wild  
type OE sequence yielded a higher increase.

As is shown in Fig. 8, which plots the tested plasmid  
against the transposition frequency ( $\times 10^{-8}$ ), little  
transposition was seen when the test plasmid included two IE  
20 termini. Somewhat higher transposition was observed when the  
test plasmid included two OE termini, particularly when the  
EK54/MA56 transposase was employed. In striking contrast, the  
combination of the EK54/MA56 transposase with either of the  
preferred selected ends (containing OE-like bases only at  
25 positions 10, 11, and 12, or positions 10, 11, 12, and 15)  
yielded a great increase in *in vivo* transposition over wild  
type OE termini.

The preferred hyperactive mutant terminus having the most  
preferred synthetic terminus sequence 5'-CTGTCTCTTATACACATCT-3'  
30 (SEQ ID NO: 8) was provided in place of both WT OE termini in  
pRZTL1 (Fig. 4) and was tested in the *in vitro* transposition  
assay of the present invention using the triple mutant  
transposase described herein. This mutant terminus was chosen  
for further *in vitro* analysis because its transposition  
35 frequency was higher than for the second preferred synthetic  
terminus and because it has no dam methylation sites, so dam  
methylation no longer affects transposition frequency. In  
contrast the 4/15/17/18 mutant does have a dam methylation  
site.

40 In a preliminary experiment, CHAPS was eliminated from the  
reaction, but the pre-incubation step was used. The reaction

5 was pre-incubated for 1 hour at 20°C, then diluted two times,  
and then incubated for 3 hours at 37°C. About 0.5 µg of DNA  
and 0.4µg of transposase was used. The transposition products  
10 were observed on a gel. With the mutant termini, very little  
of the initial DNA was observed. Numerous bands representing  
primary and secondary transposition reaction products were  
observed. The reaction mixtures were transformed into DH5α  
cells and were plated on chloramphenicol-, tetracycline-, or  
kanamycin-containing plates.

15 Six hundred forty chloramphenicol-resistant colonies were  
observed. Although these could represent unreacted plasmid,  
all such colonies tested (n=12) were sensitive to kanamycin,  
which indicates a loss of donor backbone DNA. All twelve  
colonies also included plasmids of varied size; 9 of the 12  
20 were characterized as deletion-inversions, the remaining 3 were  
simple deletions. Seventy nine tetracycline-resistant  
colonies were observed, which indicated an activation of the  
tet<sup>r</sup> gene by transposition.

Eleven kanamycin resistant colonies were observed. This  
indicated a low percentage of remaining plasmids carrying the  
25 donor backbone DNA.

In a second, similar test, about 1 µg of plasmid DNA and  
0.2 µg transposase were used. In this test, the reaction was  
incubated without CHAPS at 37°C for 3 hours without pre-  
incubation or dilution. Some initial DNA was observed in the  
30 gel after the 3 hour reaction. After overnight incubation,  
only transposition products were observed.

The 3 hour reaction products were transformed into DH5α  
cells and plated as described. About 50% of the  
chloramphenicol resistant colonies were sensitive to kanamycin  
35 and were presumably transposition products.

The invention is not intended to be limited to the  
foregoing examples, but to encompass all such modifications and  
variations as come within the scope of the appended claims.  
It is envisioned that, in addition to the uses specifically  
40 noted herein, other applications will be apparent to the  
skilled molecular biologist. In particular, methods for

5 introducing desired mutations into prokaryotic or eukaryotic  
DNA are very desirable. For example, at present it is  
difficult to knock out a functional eukaryotic gene by  
homologous recombination with an inactive version of the gene  
that resides on a plasmid. The difficulty arises from the need  
10 to flank the gene on the plasmid with extensive upstream and  
downstream sequences. Using this system, however, an  
inactivating transposable element containing a selectable  
marker gene (e.g., neo) can be introduced *in vitro* into a  
plasmid that contains the gene that one desires to inactivate.  
15 After transposition, the products can be introduced into  
suitable host cells. Using standard selection means, one can  
recover only cell colonies that contain a plasmid having the  
transposable element. Such plasmids can be screened, for  
example by restriction analysis, to recover those that contain  
20 a disrupted gene. Such clones can then be introduced directly  
into eukaryotic cells for homologous recombination and  
selection using the same marker gene.

Also, one can use the system to readily insert a PCR-  
amplified DNA fragment into a vector, thus avoiding traditional  
cloning steps entirely. This can be accomplished by (1)  
25 providing suitable a pair of PCR primers containing OE termini  
adjacent to the sequence-specific parts of the primers, (2)  
performing standard PCR amplification of a desired nucleic acid  
fragment, (3) performing the *in vitro* transposition reaction of  
the present invention using the double-stranded products of PCR  
30 amplification as the donor DNA.



## SEQUENCE LISTING

5

## (1) GENERAL INFORMATION:

(i) APPLICANT: Reznikoff, William S  
Gorysin, Igor Y  
Zhou, Hong

10

(ii) TITLE OF INVENTION: System for In Vitro Transposition

(iii) NUMBER OF SEQUENCES: 11

(iv) CORRESPONDENCE ADDRESS:

15

(A) ADDRESSEE: Quarles & Brady  
(B) STREET: 1 South Pinckney Street  
(C) CITY: Madison  
(D) STATE: WI  
(E) COUNTRY: USA  
(F) ZIP: 53703

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

30

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Berson, Bennett J  
(B) REGISTRATION NUMBER: 37094  
(C) REFERENCE/DOCKET NUMBER: 960296.94142

(ix) TELECOMMUNICATION INFORMATION:

35

(A) TELEPHONE: 608/251-5000  
(B) TELEFAX: 608-251-9166

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

40

(A) LENGTH: 1534 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Gene encoding modified Tn5  
transposase enzyme"

45

(ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION: 93..1523

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

50

CTGACTCTTA TACACAAGTA GCGTCCTGAA CGGAACCTTT CCCGTTTTCC AGGATCTGAT

60

CTTCCATGTG ACCTCCTAAC ATGGTAACGT TC ATG ATA ACT TCT GCT CTT CAT  
Met Ile Thr Ser Ala Leu His  
1 5

113

5	CGT GCG GCC GAC TGG GCT AAA TCT GTG TTC TCT TCG GCG GCG CTG GGT Arg Ala Ala Asp Trp Ala Lys Ser Val Phe Ser Ser Ala Ala Leu Gly 10 15 20	161
10	GAT CCT CGC CGT ACT GCC CGC TTG GTT AAC GTC GCC GCC CAA TTG GCA Asp Pro Arg Arg Thr Ala Arg Leu Val Asn Val Ala Ala Gln Leu Ala 25 30 35	209
	AAA TAT TCT GGT AAA TCA ATA ACC ATC TCA TCA GAG GGT AGT AAA GCC Lys Tyr Ser Gly Lys Ser Ile Thr Ile Ser Ser Glu Gly Ser Lys Ala 40 45 50 55	257
15	GCC CAG GAA GGC GCT TAC CGA TTT ATC CGC AAT CCC AAC GTT TCT GCC Ala Gln Glu Gly Ala Tyr Arg Phe Ile Arg Asn Pro Asn Val Ser Ala 60 65 70	305
	GAG GCG ATC AGA AAG GCT GGC GCC ATG CAA ACA GTC AAG TTG GCT CAG Glu Ala Ile Arg Lys Ala Gly Ala Met Gln Thr Val Lys Leu Ala Gln 75 80 85	353
20	GAG TTT CCC GAA CTG CTG GCC ATT GAG GAC ACC ACC TCT TTG AGT TAT Glu Phe Pro Glu Leu Leu Ala Ile Glu Asp Thr Thr Ser Leu Ser Tyr 90 95 100	401
25	CGC CAC CAG GTC GCC GAA GAG CTT GGC AAG CTG GGC TCT ATT CAG GAT Arg His Gln Val Ala Glu Glu Leu Gly Lys Leu Gly Ser Ile Gln Asp 105 110 115	449
	AAA TCC CGC GGA TGG TGG GTT CAC TCC GTT CTC TTG CTC GAG GCC ACC Lys Ser Arg Gly Trp Trp Val His Ser Val Leu Leu Leu Glu Ala Thr 120 125 130 135	497
30	ACA TTC CGC ACC GTA GGA TTA CTG CAT CAG GAG TGG TGG ATG CGC CCG Thr Phe Arg Thr Val Gly Leu Leu His Gln Glu Trp Trp Met Arg Pro 140 145 150	545
	GAT GAC CCT GCC GAT GCG GAT GAA AAG GAG AGT GGC AAA TGG CTG GCA Asp Asp Pro Ala Asp Ala Asp Glu Lys Glu Ser Gly Lys Trp Leu Ala 155 160 165	593
35	GCG GCC GCA ACT AGC CGG TTA CGC ATG GGC AGC ATG ATG AGC AAC GTG Ala Ala Ala Thr Ser Arg Leu Arg Met Gly Ser Met Met Ser Asn Val 170 175 180	641
40	ATT GCG GTC TGT GAC CGC GAA GCC GAT ATT CAT GCT TAT CTG CAG GAC Ile Ala Val Cys Asp Arg Glu Ala Asp Ile His Ala Tyr Leu Gln Asp 185 190 195	689
	AGG CTG GCG CAT AAC GAG CGC TTC GTG GTG CGC TCC AAG CAC CCA CGC Arg Leu Ala His Asn Glu Arg Phe Val Val Arg Ser Lys His Pro Arg 200 205 210 215	737
45	AAG GAC GTA GAG TCT GGG TTG TAT CTG ATC GAC CAT CTG AAG AAC CAA Lys Asp Val Glu Ser Gly Leu Tyr Leu Ile Asp His Leu Lys Asn Gln 220 225 230	785
	CCG GAG TTG GGT GGC TAT CAG ATC AGC ATT CCG CAA AAG GGC GTG GTG Pro Glu Leu Gly Gly Tyr Gln Ile Ser Ile Pro Gln Lys Gly Val Val 235 240 245	833
50	GAT AAA CGC GGT AAA CGT AAA AAT CGA CCA GCC CGC AAG GCG AGC TTG Asp Lys Arg Gly Lys Arg Lys Asn Arg Pro Ala Arg Lys Ala Ser Leu 250 255 260	881
55	AGC CTG CGC AGT GGG CGC ATC ACG CTA AAA CAG GGG AAT ATC ACG CTC Ser Leu Arg Ser Gly Arg Ile Thr Leu Lys Gln Gly Asn Ile Thr Leu 265 270 275	929

5	AAC GCG GTG CTG GCC GAG GAG ATT AAC CCG CCC AAG GGT GAG ACC CCG	977
	Asn Ala Val Leu Ala Glu Glu Ile Asn Pro Pro Lys Gly Glu Thr Pro	
	280 285 290 295	
10	TTG AAA TGG TTG TTG CTG ACC GGC GAA CCG GTC GAG TCG CTA GCC CAA	1025
	Leu Lys Trp Leu Leu Leu Thr Gly Glu Pro Val Glu Ser Leu Ala Gln	
	300 305 310	
	GCC TTG CGC GTC ATC GAC ATT TAT ACC CAT CGC TGG CGG ATC GAG GAG	1073
	Ala Leu Arg Val Ile Asp Ile Tyr Thr His Arg Trp Arg Ile Glu Glu	
	315 320 325	
15	TTC CAT AAG GCA TGG AAA ACC GGA GCA GGA GCC GAG AGG CAA CGC ATG	1121
	Phe His Lys Ala Trp Lys Thr Gly Ala Gly Ala Glu Arg Gln Arg Met	
	330 335 340	
	GAG GAG CCG GAT AAT CTG GAG CGG ATG GTC TCG ATC CTC TCG TTT GTT	1169
	Glu Glu Pro Asp Asn Leu Glu Arg Met Val Ser Ile Leu Ser Phe Val	
	345 350 355	
20	GCG GTC AGG CTG TTA CAG CTC AGA GAA AGC TTC ACG CCG CCG CAA GCA	1217
	Ala Val Arg Leu Leu Gln Leu Arg Glu Ser Phe Thr Pro Pro Gln Ala	
	360 365 370 375	
25	CTC AGG GCG CAA GGG CTG CTA AAG GAA GCG GAA CAC GTA GAA AGC CAG	1265
	Leu Arg Ala Gln Gly Leu Leu Lys Glu Ala Glu His Val Glu Ser Gln	
	380 385 390	
	TCC GCA GAA ACG GTG CTG ACC CCG GAT GAA TGT CAG CTA CTG GGC TAT	1313
	Ser Ala Glu Thr Val Leu Thr Pro Asp Glu Cys Gln Leu Leu Gly Tyr	
	395 400 405	
30	CTG GAC AAG GGA AAA CGC AAG CGC AAA GAG AAA GCA GGT AGC TTG CAG	1361
	Leu Asp Lys Gly Lys Arg Lys Arg Lys Glu Lys Ala Gly Ser Leu Gln	
	410 415 420	
	TGG GCT TAC ATG GCG ATA GCT AGA CTG GGC GGT TTT ATG GAC AGC AAG	1409
	Trp Ala Tyr Met Ala Ile Ala Arg Leu Gly Gly Phe Met Asp Ser Lys	
	425 430 435	
35	CGA ACC GGA ATT GCC AGC TGG GGC GCC CTC TGG GAA GGT TGG GAA GCC	1457
	Arg Thr Gly Ile Ala Ser Trp Gly Ala Leu Trp Glu Gly Trp Glu Ala	
	440 445 450 455	
40	CTG CAA AGT AAA CTG GAT GGC TTT CTT GCC GCC AAG GAT CTG ATG GCG	1505
	Leu Gln Ser Lys Leu Asp Gly Phe Leu Ala Ala Lys Asp Leu Met Ala	
	460 465 470	
	CAG GGG ATC AAG ATC TGA TCAAGAGACA G	1534
	Gln Gly Ile Lys Ile *	
	475	

## (2) INFORMATION FOR SEQ ID NO:2:

45 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 477 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Ile	Thr	Ser	Ala	Leu	His	Arg	Ala	Ala	Asp	Trp	Ala	Lys	Ser	Val
1					5				10					15	

- 34 -

5 Ser Phe Thr Pro Pro Gln Ala Leu Arg Ala Gln Gly Leu Leu Lys Glu  
 370 375 380

Ala Glu His Val Glu Ser Gln Ser Ala Glu Thr Val Leu Thr Pro Asp  
 385 390 395 400

10 Glu Cys Gln Leu Leu Gly Tyr Leu Asp Lys Gly Lys Arg Lys Arg Lys  
 405 410 415

Glu Lys Ala Gly Ser Leu Gln Trp Ala Tyr Met Ala Ile Ala Arg Leu  
 420 425 430

Gly Gly Phe Met Asp Ser Lys Arg Thr Gly Ile Ala Ser Trp Gly Ala  
 435 440 445

15 Leu Trp Glu Gly Trp Glu Ala Leu Gln Ser Lys Leu Asp Gly Phe Leu  
 450 455 460

Ala Ala Lys Asp Leu Met Ala Gln Gly Ile Lys Ile \*  
 465 470 475

## (2) INFORMATION FOR SEQ ID NO:3:

20 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 5838 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: circular

25 (ii) MOLECULE TYPE: other nucleic acid  
 (A) DESCRIPTION: /desc = "Plasmid DNA"

(vii) IMMEDIATE SOURCE:  
 (B) CLONE: pRZTL1

30 (ix) FEATURE:  
 (A) NAME/KEY: insertion\_seq  
 (B) LOCATION: 1..19

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 77..1267  
 (D) OTHER INFORMATION: /function= "tetracycline resistance"

35 (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: complement (2301..2960)  
 (D) OTHER INFORMATION: /function= "chloramphenicol resistance"

40 (ix) FEATURE:  
 (A) NAME/KEY: insertion\_seq  
 (B) LOCATION: 4564..4582

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 4715..5530  
 (D) OTHER INFORMATION: /function= "kanamycin resistance"

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTGACTCTTA TACACAAGTA AGCTTTAATG CGGTAGTTTA TCACAGTTAA ATTGCTAACG 60

CAGTCAGGCA CCGTGT ATG AAA TCT AAC AAT GCG CTC ATC GTC ATC CTC 109

50 Met Lys Ser Asn Asn Ala Leu Ile Val Ile Leu  
 480 485

5	GGC ACC GTC ACC CTG GAT GCT GTA GGC ATA GGC TTG GTT ATG CCG GTA Gly Thr Val Thr Leu Asp Ala Val Gly Ile Gly Leu Val Met Pro Val 490 495 500	157
10	CTG CCG GGC CTC TTG CGG GAT ATC GTC CAT TCC GAC AGC ATC GCC AGT Leu Pro Gly Leu Leu Arg Asp Ile Val His Ser Asp Ser Ile Ala Ser 505 510 515 520	205
	CAC TAT GGC GTG CTG CTA GCG CTA TAT GCG TTG ATG CAA TTT CTA TGC His Tyr Gly Val Leu Leu Ala Leu Tyr Ala Leu Met Gln Phe Leu Cys 525 530 535	253
15	GCA CCC GTT CTC GGA GCA CTG TCC GAC CGC TTT GGC CGC CGC CCA GTC Ala Pro Val Leu Gly Ala Leu Ser Asp Arg Phe Gly Arg Arg Pro Val 540 545 550	301
	CTG CTC GCT TCG CTA CTT GGA GCC ACT ATC GAC TAC GCG ATC ATG GCG Leu Leu Ala Ser Leu Leu Gly Ala Thr Ile Asp Tyr Ala Ile Met Ala 555 560 565	349
20	ACC ACA CCC GTC CTG TGG ATC CTC TAC GCC GGA CGC ATC GTG GCC GGC Thr Thr Pro Val Leu Trp Ile Leu Tyr Ala Gly Arg Ile Val Ala Gly 570 575 580	397
25	ATC ACC GGC GCC ACA GGT GCG GTT GCT GGC GCC TAT ATC GCC GAC ATC Ile Thr Gly Ala Thr Gly Ala Val Ala Gly Ala Tyr Ile Ala Asp Ile 585 590 595 600	445
	ACC GAT GGG GAA GAT CGG GCT CGC CAC TTC GGG CTC ATG AGC GCT TGT Thr Asp Gly Glu Asp Arg Ala Arg His Phe Gly Leu Met Ser Ala Cys 605 610 615	493
30	TTC GGC GTG GGT ATG GTG GCA GGC CCC GTG GCC GGG GGA CTG TTG GGC Phe Gly Val Gly Met Val Ala Gly Pro Val Ala Gly Gly Leu Leu Gly 620 625 630	541
	GCC ATC TCC TTG CAT GCA CCA TTC CTT GCG GCG GCG GTG CTC AAC GGC Ala Ile Ser Leu His Ala Pro Phe Leu Ala Ala Ala Val Leu Asn Gly 635 640 645	589
35	CTC AAC CTA CTA CTG GGC TGC TTC CTA ATG CAG GAG TCG CAT AAG GGA Leu Asn Leu Leu Leu Gly Cys Phe Leu Met Gln Glu Ser His Lys Gly 650 655 660	637
40	GAG CGT CGA CCG ATG CCC TTG AGA GCC TTC AAC CCA GTC AGC TCC TTC Glu Arg Arg Pro Met Pro Leu Arg Ala Phe Asn Pro Val Ser Ser Phe 665 670 675 680	685
	CGG TGG GCG CGG GGC ATG ACT ATC GTC GCC GCA CTT ATG ACT GTC TTC Arg Trp Ala Arg Gly Met Thr Ile Val Ala Ala Leu Met Thr Val Phe 685 690 695	733
45	TTT ATC ATG CAA CTC GTA GGA CAG GTG CCG GCA GCG CTC TGG GTC ATT Phe Ile Met Gln Leu Val Gly Gln Val Pro Ala Ala Leu Trp Val Ile 700 705 710	781
	TTC GGC GAG GAC CGC TTT CGC TGG AGC GCG ACG ATG ATC GGC CTG TCG Phe Gly Glu Asp Arg Phe Arg Trp Ser Ala Thr Met Ile Gly Leu Ser 715 720 725	829
50	CTT GCG GTA TTC GGA ATC TTG CAC GCC CTC GCT CAA GCC TTC GTC ACT Leu Ala Val Phe Gly Ile Leu His Ala Leu Ala Gln Ala Phe Val Thr 730 735 740	877
55	GGT CCC GCC ACC AAA CGT TTC GGC GAG AAG CAG GCC ATT ATC GCC GGC Gly Pro Ala Thr Lys Arg Phe Gly Glu Lys Gln Ala Ile Ile Ala Gly 745 750 755 760	925

5	ATG GCG GCC GAC GCG CTG GGC TAC GTC TTG CTG GCG TTC GCG ACG CGA Met Ala Ala Asp Ala Leu Gly Tyr Val Leu Leu Ala Phe Ala Thr Arg 765 770 775	973
10	GGC TGG ATG GCC TTC CCC ATT ATG ATT CTT CTC GCT TCC GGC GGC ATC Gly Trp Met Ala Phe Pro Ile Met Ile Leu Leu Ala Ser Gly Gly Ile 780 785 790	1021
	GGG ATG CCC GCG TTG CAG GCC ATG CTG TCC AGG CAG GTA GAT GAC GAC Gly Met Pro Ala Leu Gln Ala Met Leu Ser Arg Gln Val Asp Asp Asp 795 800 805	1069
15	CAT CAG GGA CAG CTT CAA GGA TCG CTC GCG GCT CTT ACC AGC CTA ACT His Gln Gly Gln Leu Gln Gly Ser Leu Ala Ala Leu Thr Ser Leu Thr 810 815 820	1117
	TCG ATC ACT GGA CCG CTG ATC GTC ACG GCG ATT TAT GCC GCC TCG GCG Ser Ile Thr Gly Pro Leu Ile Val Thr Ala Ile Tyr Ala Ala Ser Ala 825 830 835 840	1165
20	AGC ACA TGG AAC GGG TTG GCA TGG ATT GTA GGC GCC GCC CTA TAC CTT Ser Thr Trp Asn Gly Leu Ala Trp Ile Val Gly Ala Ala Leu Tyr Leu 845 850 855	1213
25	GTC TGC CTC CCC GCG TTG CGT CGC GGT GCA TGG AGC CGG GCC ACC TCG Val Cys Leu Pro Ala Leu Arg Arg Gly Ala Trp Ser Arg Ala Thr Ser 860 865 870	1261
	ACC TGA ATGGAAGCCG GCGGCACCTC GCTAACGGAT TCACCACTCC AAGAATTGGA Thr *	1317
30	GCCAATCAAT TCTTGCGGAG AACTGTGAAT GCGCAAACCA ACCCTTGGCA GAACATATCC	1377
	ATCGCGTCCG CCATCTCCAG CAGCCGCACG CGGCGCATCT CGGGCAGCGT TGGGTCCTGG	1437
	CCACGGGTGC GCATGATCGT GCTCCTGTCTG TTGAGGACCC GGCTAGGCTG GCGGGGTTGC	1497
	CTTACTGGTT AGCAGAATGA ATCACCGATA CGCGAGCGAA CGTGAAGCGA CTGCTGCTGC	1557
	AAAACGTCTG CGACCTGAGC AACAACATGA ATGGTCTTCG GTTTCCGTGT TTCGTAAAGT	1617
	CTGGAAACGC GGAAGTCCCC TACGTGCTGC TGAAGTTGCC CGCAACAGAG AGTGGAACCA	1677
35	ACCGGTGATA CCACGATACT ATGACTGAGA GTCAACGCCA TGAGCGGCCT CATTTCTTAT	1737
	TCTGAGTTAC AACAGTCCGC ACCGCTGTCC GGTAGCTCCT TCCGGTGGGC GCGGGGCATG	1797
	ACTATCGTCG CCGCACTTAT GACTGTCTTC TTTATCATGC AACTCGTAGG ACAGGTGCCG	1857
	GCAGCGCCCA ACAGTCCCCC GGCCACGGGG CCTGCCACCA TACCCACGCC GAAACAAGCG	1917
	CCCTGCACCA TTATGTTCCG GATCTGCATC GCAGGATGCT GCTGGCTACC CTGTGGAACA	1977
40	CCTACATCTG TATTAACGAA GCGCTAACCG TTTTATCAG GCTCTGGGAG GCAGAATAAA	2037
	TGATCATATC GTCAATTATT ACCTCCACGG GGAGAGCCTG AGCAAACTGG CCTCAGGCAT	2097
	TTGAGAAGCA CACGGTCACA CTGCTTCCGG TAGTCAATAA ACCGGTAAAC CAGCAATAGA	2157
	CATAAGCGGC TATTTAACGA CCCTGCCCTG AACCGACGAC CGGGTCGAAT TTGCTTTTGA	2217
	ATTTCTGCCA TTCATCCGCT TATTATCAAT TATTCAGGCG TAGCACCAGG CGTTTAAGGG	2277
45	CACCAATAAC TGCCTTAAAA AAATTACGCC CCGCCCTGCC ACTCATCGCA GTACTGTTGT	2337
	AATTCATTAA GCATTCTGCC GACATGGAAG CCATCACAGA CGGCATGATG AACCTGAATC	2397

5	GCCAGCGGCA TCAGCACCTT GTCGCCTTGC GTATAATATT TGCCCATGGT GAAAACGGGG	2457
	GCGAAGAAGT TGTCCATATT GGCCACGTTT AAATCAAAAC TGGTGAAACT CACCCAGGGA	2517
	TTGGCTGAGA CGAAAAACAT ATTCTCAATA AACCCTTTAG GGAAATAGGC CAGGTTTTCA	2577
	CCGTAACACG CCACATCTTG CGAATATATG TG TAGAAACT GCCGGAAATC GTCGTGGTAT	2637
	TCACTCCAGA GCGATGAAAA CGTTTCAGTT TGCTCATGGA AAACGGTGTA ACAAGGGTGA	2697
10	ACACTATCCC ATATCACCAG CTCACCGTCT TTCATTGCCA TACGGAATTC CGGATGAGCA	2757
	TTCATCAGGC GGGCAAGAAT GTGAATAAAG GCCGGATAAA ACTTGTGCTT ATTTTTCTTT	2817
	ACGGTCTTTA AAAAGGCCGT AATATCCAGC TGAACGGTCT GGTATAGGT ACATTGAGCA	2877
	ACTGACTGAA ATGCCTCAA ATGTTCTTTA CGATGCCATT GGGATATATC AACGGTGGTA	2937
	TATCCAGTGA TTTTTTCTC CATTTTAGCT TCCTTAGCTC CTGAAAATCT CGATAACTCA	2997
15	AAAAATACGC CCGGTAGTGA TCTTATTTCA TTATGGTGAA AGTTGGAACC TCTTACGTGC	3057
	CGATCAACGT CTCATTTTCG CCAAAGTTG GCCCAGGGCT TCCCGGTATC AACAGGGACA	3117
	CCAGGATTTA TTTATTCTGC GAAGTGATCT TCCGTCACAG GTATTTATTC GGCAGCAAGT	3177
	GCGTCGGGTG ATGCTGCCAA CTTACTGATT TAGTGTATGA TGGTGTTTTT GAGGTGCTCC	3237
	AGTGGCTTCT GTTTCTATCA GCTGTCCCTC CTGTTACAGT ACTGACGGGG TGGTGCGTAA	3297
20	CGGCAAAAGC ACCGCCGGAC ATCAGCGCTA GCGGAGTGTA TACTGGCTTA CTATGTTGGC	3357
	ACTGATGAGG GTGTCAGTGA AGTGCTTCAT GTGGCAGGAG AAAAAAGGCT GCACCGGTGC	3417
	GTCAGCAGAA TATGTGATAC AGGATATATT CCGCTTCCTC GCTCACTGAC TCGCTACGCT	3477
	CGGTGCTTCG ACTGCGGCGA GCGGAAATGG CTTACGAACG GGGCGGAGAT TTCCTGGAAG	3537
	ATGCCAGGAA GATACTTAAC AGGGAAGTGA GAGGGCCGCG GCAAAGCCGT TTTTCCATAG	3597
25	GCTCCGCCCC CCTGACAAGC ATCAGCAAAT CTGACGCTCA AATCAGTGGT GGCGAAACCC	3657
	GACAGGACTA TAAAGATACC AGGCGTTTCC CCTGGCGGCT CCCTCGTGCG CTCTCCTGTT	3717
	CCTGCCTTTC GGTTTACCGG TGTCATTCCG CTGTTATGGC CGCGTTTGTC TCATTCCACG	3777
	CCTGACACTC AGTTCCGGGT AGGCAGTTCG CTCCAAGCTG GACTGTATGC ACGAACCCCC	3837
	CGTTCAGTCC GACCGCTGCG CTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGAAAG	3897
30	ACATGCAAAA GCACCACTGG CAGCAGCCAC TGGTAATTGA TTTAGAGGAG TTAGTCTTGA	3957
	AGTCATGCGC CGGTTAAGGC TAAACTGAAA GGACAAGTTT TGGTGACTGC GCTCCTCCAA	4017
	GCCAGTTACC TCGGTTCAAA GAGTTGGTAG CTCAGAGAAC CTTGAAAAA CCGCCCTGCA	4077
	AGGCGGTTTT TTCGTTTTCA GAGCAAGAGA TTACGCGCAG ACCAAAACGA TCTCAAGAAG	4137
	ATCATCTTAT TAATCAGATA AAATATTTCT AGAGGTGAAC CATCACCCTA ATCAAGTTTT	4197
35	TTGGGGTCGA GGTGCCGTAA AGCACTAAAT CGGAACCCTA AAGGGATGCC CCGATTTAGA	4257
	GCTTGACGGG GAAAGCCGGC GAACGTGGCG AGAAAGGAAG GGAAGAAAGC GAAAGGAGCG	4317
	GGCGCTAGGG CGCTGGCAAG TG TAGCGGTC ACGCTGCGCG TAACCACCAC ACCCGCCGCG	4377
	CTTAATGCGC CGCTACAGCG CCATTCGCCA TTCAGGCTGC GCAACTGTTG GGAAGGGCGA	4437



5	TCGGTGC GGG CCTCTTCGCT ATTACGCCAG CTGGCGAAAG GGGGATGTGC TGCAAGGCCGA	4497
	TTAAGTTGGG TAACGCCAGG GTTTTCCCAG TCACGACGTT GTAAAACGAC GGCCAGTGCC	4557
	AAGCTTACTT GTGTATAAGA GTCAGTCGAC CTGCAGGGGG GGGGGGAAA GCCACGTTGT	4617
	GTCTCAAAAT CTCTGATGTT ACATTGCACA AGATAAAAAT ATATCATCAT GAACAATAAA	4677
10	ACTGTCTGCT TACATAAACA GTAATACAAG GGGTGTGTT ATG AGC CAT ATT CAA CGG Met Ser His Ile Gln Arg 1 5	4732
	GAA ACG TCT TGC TCG AGG CCG CGA TTA AAT TCC AAC ATG GAT GCT GAT Glu Thr Ser Cys Ser Arg Pro Arg Leu Asn Ser Asn Met Asp Ala Asp 10 15 20	4780
15	TTA TAT GGG TAT AAA TGG GCT CGC GAT AAT GTC GGG CAA TCA GGT GCG Leu Tyr Gly Tyr Lys Trp Ala Arg Asp Asn Val Gly Gln Ser Gly Ala 25 30 35	4828
	ACA ATC TAT CGA TTG TAT GGG AAG CCC GAT GCG CCA GAG TTG TTT CTG Thr Ile Tyr Arg Leu Tyr Gly Lys Pro Asp Ala Pro Glu Leu Phe Leu 40 45 50	4876
20	AAA CAT GGC AAA GGT AGC GTT GCC AAT GAT GTT ACA GAT GAG ATG GTC Lys His Gly Lys Gly Ser Val Ala Asn Asp Val Thr Asp Glu Met Val 55 60 65 70	4924
25	AGA CTA AAC TGG CTG ACG GAA TTT ATG CCT CTT CCG ACC ATC AAG CAT Arg Leu Asn Trp Leu Thr Glu Phe Met Pro Leu Pro Thr Ile Lys His 75 80 85	4972
	TTT ATC CGT ACT CCT GAT GAT GCA TGG TTA CTC ACC ACT GCG ATC CCC Phe Ile Arg Thr Pro Asp Asp Ala Trp Leu Leu Thr Thr Ala Ile Pro 90 95 100	5020
30	GGG AAA ACA GCA TTC CAG GTA TTA GAA GAA TAT CCT GAT TCA GGT GAA Gly Lys Thr Ala Phe Gln Val Leu Glu Glu Tyr Pro Asp Ser Gly Glu 105 110 115	5068
35	AAT ATT GTT GAT GCG CTG GCA GTG TTC CTG CGC CGG TTG CAT TCG ATT Asn Ile Val Asp Ala Leu Ala Val Phe Leu Arg Arg Leu His Ser Ile 120 125 130	5116
	CCT GTT TGT AAT TGT CCT TTT AAC AGC GAT CGC GTA TTT CGT CTC GCT Pro Val Cys Asn Cys Pro Phe Asn Ser Asp Arg Val Phe Arg Leu Ala 135 140 145 150	5164
40	CAG GCG CAA TCA CGA ATG AAT AAC GGT TTG GTT GAT GCG AGT GAT TTT Gln Ala Gln Ser Arg Met Asn Asn Gly Leu Val Asp Ala Ser Asp Phe 155 160 165	5212
	GAT GAC GAG CGT AAT GGC TGG CCT GTT GAA CAA GTC TGG AAA GAA ATG Asp Asp Glu Arg Asn Gly Trp Pro Val Glu Gln Val Trp Lys Glu Met 170 175 180	5260
45	CAT AAG CTT TTG CCA TTC TCA CCG GAT TCA GTC GTC ACT CAT GGT GAT His Lys Leu Leu Pro Phe Ser Pro Asp Ser Val Val Thr His Gly Asp 185 190 195	5308
50	TTC TCA CTT GAT AAC CTT ATT TTT GAC GAG GGG AAA TTA ATA GGT TGT Phe Ser Leu Asp Asn Leu Ile Phe Asp Glu Gly Lys Leu Ile Gly Cys 200 205 210	5356
	ATT GAT GTT GGA CGA GTC GGA ATC GCA GAC CGA TAC CAG GAT CTT GCC Ile Asp Val Gly Arg Val Gly Ile Ala Asp Arg Tyr Gln Asp Leu Ala 215 220 225 230	5404

5 ATC CTA TGG AAC TGC CTC GGT GAG TTT TCT CCT TCA TTA CAG AAA CGG 5452  
 Ile Leu Trp Asn Cys Leu Gly Glu Phe Ser Pro Ser Leu Gln Lys Arg  
 235 240 245

10 CTT TTT CAA AAA TAT GGT ATT GAT AAT CCT GAT ATG AAT AAA TTG CAG 5500  
 Leu Phe Gln Lys Tyr Gly Ile Asp Asn Pro Asp Met Asn Lys Leu Gln  
 250 255 260

TTT CAT TTG ATG CTC GAT GAG TTT TTC TAA TCAGAATTGG TTAATTGGTT 5550  
 Phe His Leu Met Leu Asp Glu Phe Phe \*

265 270

15 GTAACACTGG CAGAGCATTA CGCTGACTTG ACGGGACGGC GGCTTTGTTG AATAAATCGA 5610  
 ACTTTTGCTG AGTTGAAGGA TCAGATCACG CATCTTCCCG ACAACGCAGA CCGTTCCTG 5670  
 GCAAAGCAAA AGTTCAAAT CACCAACTGG TCCACCTACA ACAAAGCTCT CATCAACCGT 5730  
 GGCTCCCTCA CTTTCTGGCT GGATGATGGG GCGATTGAGG CCTGGTATGA GTCAGCAACA 5790  
 CCTTCTTCAC GAGGCAGACC TCAGCGCCCC CCCCCCCTG CAGGTCGA 5838

(2) INFORMATION FOR SEQ ID NO:4:

20 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 397 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Lys Ser Asn Asn Ala Leu Ile Val Ile Leu Gly Thr Val Thr Leu  
 1 5 10 15  
 Asp Ala Val Gly Ile Gly Leu Val Met Pro Val Leu Pro Gly Leu Leu  
 20 25 30  
 Arg Asp Ile Val His Ser Asp Ser Ile Ala Ser His Tyr Gly Val Leu  
 35 40 45  
 Leu Ala Leu Tyr Ala Leu Met Gln Phe Leu Cys Ala Pro Val Leu Gly  
 50 55 60  
 Ala Leu Ser Asp Arg Phe Gly Arg Arg Pro Val Leu Leu Ala Ser Leu  
 65 70 75 80  
 Leu Gly Ala Thr Ile Asp Tyr Ala Ile Met Ala Thr Thr Pro Val Leu  
 85 90 95  
 Trp Ile Leu Tyr Ala Gly Arg Ile Val Ala Gly Ile Thr Gly Ala Thr  
 100 105 110  
 Gly Ala Val Ala Gly Ala Tyr Ile Ala Asp Ile Thr Asp Gly Glu Asp  
 115 120 125  
 Arg Ala Arg His Phe Gly Leu Met Ser Ala Cys Phe Gly Val Gly Met  
 130 135 140  
 Val Ala Gly Pro Val Ala Gly Gly Leu Leu Gly Ala Ile Ser Leu His  
 145 150 155 160  
 Ala Pro Phe Leu Ala Ala Val Leu Asn Gly Leu Asn Leu Leu Leu  
 165 170 175

5 Gly Cys Phe Leu Met Gln Glu Ser His Lys Gly Glu Arg Arg Pro Met  
180 185 190

Pro Leu Arg Ala Phe Asn Pro Val Ser Ser Phe Arg Trp Ala Arg Gly  
195 200 205

10 Met Thr Ile Val Ala Ala Leu Met Thr Val Phe Phe Ile Met Gln Leu  
210 215 220

Val Gly Gln Val Pro Ala Ala Leu Trp Val Ile Phe Gly Glu Asp Arg  
225 230 235 240

Phe Arg Trp Ser Ala Thr Met Ile Gly Leu Ser Leu Ala Val Phe Gly  
245 250 255

15 Ile Leu His Ala Leu Ala Gln Ala Phe Val Thr Gly Pro Ala Thr Lys  
260 265 270

Arg Phe Gly Glu Lys Gln Ala Ile Ile Ala Gly Met Ala Ala Asp Ala  
275 280 285

20 Leu Gly Tyr Val Leu Leu Ala Phe Ala Thr Arg Gly Trp Met Ala Phe  
290 295 300

Pro Ile Met Ile Leu Leu Ala Ser Gly Gly Ile Gly Met Pro Ala Leu  
305 310 315 320

Gln Ala Met Leu Ser Arg Gln Val Asp Asp Asp His Gln Gly Gln Leu  
325 330 335

25 Gln Gly Ser Leu Ala Ala Leu Thr Ser Leu Thr Ser Ile Thr Gly Pro  
340 345 350

Leu Ile Val Thr Ala Ile Tyr Ala Ala Ser Ala Ser Thr Trp Asn Gly  
355 360 365

30 Leu Ala Trp Ile Val Gly Ala Ala Leu Tyr Leu Val Cys Leu Pro Ala  
370 375 380

Leu Arg Arg Gly Ala Trp Ser Arg Ala Thr Ser Thr \*

385 390 395

## (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 220 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

40 Met Glu Lys Lys Ile Thr Gly Tyr Thr Thr Val Asp Ile Ser Gln Trp  
1 5 10 15

His Arg Lys Glu His Phe Glu Ala Phe Gln Ser Val Ala Gln Cys Thr  
20 25 30

45 Tyr Asn Gln Thr Val Gln Leu Asp Ile Thr Ala Phe Leu Lys Thr Val  
35 40 45

Lys Lys Asn Lys His Lys Phe Tyr Pro Ala Phe Ile His Ile Leu Ala  
50 55 60

Arg Leu Met Asn Ala His Pro Glu Phe Arg Met Ala Met Lys Asp Gly  
65 70 75 80

(2) INFORMATION FOR SEQ ID NO:6:

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

-42-

5 Val Asp Ala Ser Asp Phe Asp Asp Glu Arg Asn Gly Trp Pro Val Glu  
165 170  
Gln Val Trp Lys Glu Met His Lys Leu Leu Pro Phe Ser Pro Asp Ser  
180 185 190  
10 Val Val Thr His Gly Asp Phe Ser Leu Asp Asn Leu Ile Phe Asp Glu  
195 200 205  
Gly Lys Leu Ile Gly Cys Ile Asp Val Gly Arg Val Gly Ile Ala Asp  
210 215 220  
Arg Tyr Gln Asp Leu Ala Ile Leu Trp Asn Cys Leu Gly Glu Phe Ser  
225 230 235 240  
15 Pro Ser Leu Gln Lys Arg Leu Phe Gln Lys Tyr Gly Ile Asp Asn Pro  
245 250 255  
Asp Met Asn Lys Leu Gln Phe His Leu Met Leu Asp Glu Phe Phe \*  
260 265 270

## (2) INFORMATION FOR SEQ ID NO:7:

- 20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear
- 25 (ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "Tn5 wild type outside end"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTGACTCTTA TACACAAGT

19

## (2) INFORMATION FOR SEQ ID NO:8:

- 30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear
- 35 (ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "Tn5 mutant outside end"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTGTCTCTTA TACACATCT

19

## (2) INFORMATION FOR SEQ ID NO:9:

- 40 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear
- 45 (ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "Tn5 mutant outside end"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTGTCTCTTA TACAGATCT

19

## 5 (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 19 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid  
 (A) DESCRIPTION: /desc = "Tn5 wild type inside end"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CTGTCTCTTG ATCAGATCT

19

## 15 (2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 19182 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: circular

- (ii) MOLECULE TYPE: other nucleic acid  
 (A) DESCRIPTION: /desc = "Plasmid pRZ4196"

- (ix) FEATURE:  
 (A) NAME/KEY: repeat\_unit  
 (B) LOCATION: 94..112  
 (D) OTHER INFORMATION: /note= "Wild type OE sequence"

- (ix) FEATURE:  
 (A) NAME/KEY: repeat\_unit  
 (B) LOCATION: 12184..12225  
 (D) OTHER INFORMATION: /note= "Cassette IE"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TTCCTGTAAC AATAGCAATA CCCCAAATAC CTAATGTAGT TCCAGCAAGC AAGCTAAAAA	60
GTAAAGCAAC AACATAACTC ACCCTGTCAT CTGCTGACTC TTATACACAA GTAGCGTCCC	120
GGGATCGGGA TCCCGTCGTT TTACAACGTC GTGACTGGGA AAACCCTGGC GTTACCCAAC	180
TTAATCGCCT TGCAGCACAT CCCCTTTTCG CCAGCTGGCG TAATAGCGAA GAGGCCCGCA	240
CCGATCGCCC TTCCAACAG TTGCGCAGCC TGAATGGCGA ATGGCGCTTT GCCTGGTTTC	300
CGGCACCAGA AGCGGTGCCG GAAAGCTGGC TGGAGTGCGA TCTTCCTGAG GCCGATACTG	360
TCGTCGTCCC CTCAAACCTGG CAGATGCACG GTTACGATGC GCCCATCTAC ACCAACGTAA	420
CCTATCCCAT TACGGTCAAT CCGCCGTTTG TTCCACGGA GAATCCGACG GGTGTGTTACT	480
CGCTCACATT TAATGTTGAT GAAAGCTGGC TACAGGAAGG CCAGACGCGA ATTATTTTGTG	540
ATGGCGTTAA CTCGGCGTTT CATCTGTGGT GCAACGGGCG CTGGGTCGGT TACGGCCAGG	600
ACAGTCGTTT GCCGTCTGAA TTTGACCTGA GCGCATTTTT ACGCGCCGGA GAAAACCGCC	660
TCGCGGTGAT GGTGCTGCGT TGGAGTGACG GCAGTTATCT GGAAGATCAG GATATGTGGC	720
GGATGAGCGG CATTTTCCGT GACGTCTCGT TGCTGCATAA ACCGACTACA CAAATCAGCG	780
ATTTCCATGT TGCCACTCGC TTTAATGATG ATTTAGCCG CGCTGTACTG GAGGCTGAAG	840
TTCAGATGTG CGGCGAGTTG CGTGA CTACC TACGGGTAAC AGTTTCTTTA TGGCAGGGTG	900

5	AAACGCAGGT CGCCAGCGGC ACCGCGCCTT TCGGCGGTGA AATTATCGAT GAGCGTGGTG	960
	GTTATGCCGA TCGCGTCACA CTACGTCTGA ACGTCGAAAA CCCGAACTG TGGAGCGCCG	1020
	AAATCCCGAA TCTCTATCGT GCGGTGGTTG AACTGCACAC CGCCGACGGC ACGCTGATTG	1080
	AAGCAGAAGC CTGCGATGTC GGTTCGCGC AGGTGCGGAT TGAAAATGGT CTGCTGCTGC	1140
	TGAACGGCAA GCCGTTGCTG ATTCGAGGCG TTAACCGTCA CGAGCATCAT CCTCTGCATG	1200
10	GTCAGGTCAT GGATGAGCAG ACGATGGTGC AGGATATCCT GCTGATGAAG CAGAACAAC	1260
	TTAACGCCGT GCGCTGTTCG CATTATCCGA ACCATCCGCT GTGGTACACG CTGTGCGACC	1320
	GCTACGGCCT GTATGTGGTG GATGAAGCCA ATATTGAAAC CCACGGCATG GTGCCAATGA	1380
	ATCGTCTGAC CGATGATCCG CGCTGGCTAC CGGCGATGAG CGAACGCGTA ACGCGAATGG	1440
	TGCAGCGCGA TCGTAATCAC CCGAGTGTGA TCATCTGGTC GCTGGGGAAT GAATCAGGCC	1500
15	ACGGCGCTAA TCACGACGCG CTGTATCGCT GGATCAAATC TGTCGATCCT TCCCGCCCGG	1560
	TGCAGTATGA AGGCGGCGGA GCCGACACCA CGGCCACCGA TATTATTTGC CCGATGTACG	1620
	CGCGCGTGGA TGAAGACCAG CCCTTCCCGG CTGTGCCGAA ATGGTCCATC AAAAAATGGC	1680
	TTTCGCTACC TGGAGAGACG CGCCCGCTGA TCCTTTGCGA ATACGCCAC GCGATGGGTA	1740
	ACAGTCTTGG CGGTTTCGCT AAATACTGGC AGGCGTTTCG TCAGTATCCC CGTTTACAGG	1800
20	GCGGCTTCGT CTGGGACTGG GTGGATCAGT CGCTGATTAA ATATGATGAA AACGGCAACC	1860
	CGTGGTCGGC TTACGGCGGT GATTTTGGCG ATACGCCGAA CGATCGCCAG TTCTGTATGA	1920
	ACGGTCTGGT CTTTGCCGAC CGCACGCCGC ATCCAGCGCT GACGGAAGCA AAACACCAGC	1980
	AGCAGTTTTT CCAGTTCCGT TTATCCGGGC AAACCATCGA AGTGACCAGC GAATACCTGT	2040
	TCCGTCATAG CGATAACGAG CTCCTGCACT GGATGGTGGC GCTGGATGGT AAGCCGCTGG	2100
25	CAAGCGGTGA AGTGCCCTCTG GATGTCGCTC CACAAGGTAA ACAGTTGATT GAACTGCCTG	2160
	AACTACCGCA GCCGGAGAGC GCCGGGCAAC TCTGGCTCAC AGTACGCGTA GTGCAACCGA	2220
	ACGCGACCGC ATGGTCAGAA GCCGGGCACA TCAGCGCCTG GCAGCAGTGG CGTCTGGCGG	2280
	AAAACCTCAG TGTGACGCTC CCCGCCGCGT CCCACGCCAT CCCGCATCTG ACCACCAGCG	2340
	AAATGGATTT TTGCATCGAG CTGGGTAATA AGCGTTGGCA ATTTAACCGC CAGTCAGGCT	2400
30	TTCTTTCACA GATGTGGATT GGCGATAAAA ACAAACCTGCT GACGCCGCTG CGCGATCAGT	2460
	TCACCCGTGC ACCGCTGGAT AACGACATTG GCGTAAGTGA AGCGACCCGC ATTGACCTTA	2520
	ACGCCTGGGT CGAACGCTGG AAGGCGGCGG GCCATTACCA GGCCGAAGCA GCGTTGTTGC	2580
	AGTGCACGGC AGATACACTT GCTGATGCGG TGCTGATTAC GACCGCTCAC GCGTGGCAGC	2640
	ATCAGGGGAA AACCTTATTT ATCAGCCGGA AAACCTACCG GATTGATGGT AGTGGTCAAA	2700
35	TGGCGATTAC CGTTGATGTT GAAGTGCGGA GCGATACACC GCATCCGGCG CGGATTGGCC	2760
	TGAACTGCCA GCTGGCGCAG GTAGCAGAGC GGGTAACTG GCTCGGATTA GGGCCGCAAG	2820
	AAAACCTATCC CGACCGCCTT ACTGCCGCCT GTTTTGACCG CTGGGATCTG CCATTGTCAG	2880
	ACATGTATAC CCCGTACGTC TTCCCAGCG AAAACGGTCT GCGCTGCGGG ACGCGCGAAT	2940

5	TGAATTATGG CCCACACCAG TGGCGCGGCG ACTTCCAGTT CAACATCAGC CGCTACAGTC	3000
	AACAGCAACT GATGGAAACC AGCCATCGCC ATCTGCTGCA CGCGGAAGAA GGCACATGGC	3060
	TGAATATCGA CGGTTTCCAT ATGGGGATTG GTGGCGACGA CTCCTGGAGC CCGTCAGTAT	3120
	CGGCGGATTC CAGCTGAGCG CCGGTCGCTA CCATTACCAG TTGGTCTGGT GTCAAAAATA	3180
	ATAATAACCG GGCAGGCCAT GTCTGCCCGT ATTTGCGGTA AGGAAATCCA TTATGTACTA	3240
10	TTTAAAAAAC ACAAACTTTT GGATGTTTCG TTTATTCTTT TTCTTTTACT TTTTATCAT	3300
	GGGAGCCTAC TTCCCGTTTT TCCCGATTTC GCTACATGAC ATCAACCATA TCAGCAAAAG	3360
	TGATACGGGT ATTATTTTTG CCGCTATTTT TCTGTTCTCG CTATTATTCC AACCGCTGTT	3420
	TGGTCTGCTT TCTGACAAAC TCGGGCTGCG CAAATACCTG CTGTGGATTA TTACCGGCAT	3480
	GTTAGTGATG TTTGCGCCGT TCTTTATTTT TATCTTCGGG CCACTGTTAC AATACAACAT	3540
15	TTTAGTAGGA TCGATTGTTG GTGGTATTTA TCTAGGCTTT TGTTTTAACG CCGGTGCGCC	3600
	AGCAGTAGAG GCATTTATTG AGAAAGTCAG CCGTCGCAGT AATTTGGAAT TTGGTCGCGC	3660
	GCGGATGTTT GGCTGTGTTG GCTGGGCGCT GTGTGCCTCG ATTGTGCGCA TCATGTTTAC	3720
	CATCAATAAT CAGTTTGTTT TCTGGCTGGG CTCTGGCTGT GCACTCATCC TCGCCGTTTT	3780
	ACTCTTTTTC GCCAAAACGG ATGCGCCCTC TTCTGCCACG GTTGCCAATG CGGTAGGTGC	3840
20	CAACCATTCG GCATTTAGCC TTAAGCTGGC ACTGGAACTG TTCAGACAGC CAAAACGTG	3900
	GTTTTTGTC CTGTATGTTA TTGGCGTTTC CTGCACCTAC GATGTTTTTG ACCAACAGTT	3960
	TGCTAATTTT TTTACTTCGT TCTTTGCTAC CCGTGAACAG GGTACGCGGG TATTTGGCTA	4020
	CGTAACGACA ATGGGCGAAT TACTTAACGC CTCGATTATG TTCTTTGCGC CACTGATCAT	4080
	TAATCGCATC GGTGGGAAAA ACGCCCTGCT GCTGGCTGGC ACTATTATGT CTGTACGTAT	4140
25	TATTGGCTCA TCGTTCGCCA CCTCAGCGCT GGAAGTGGTT ATTCTGAAAA CGCTGCATAT	4200
	GTTTGAAGTA CCGTTCCTGC TGGTGGGCTG CTTTAAATAT ATTACCAGCC AGTTTGAAGT	4260
	GCGTTTTTCA GCGACGATTT ATCTGGTCTG TTTCTGCTTC TTTAAGCAAC TGGCGATGAT	4320
	TTTTATGTCT GACTGGCGG GCAATATGTA TGAAAGCATC GGTTTCCAGG GCGCTTATCT	4380
	GGTGCTGGGT CTGGTGGCGC TGGGCTTCAC CTTAATTTCC GTGTTACGC TTAGCGGCCC	4440
30	CGGCCCCTT TCCCTGCTGC GTCGTCAGGT GAATGAAGTC GCTTAAGCAA TCAATGTCGG	4500
	ATGCGGCGCG ACGCTTATCC GACCAACATA TCATAACGGA GTGATCGCAT TGAACATGCC	4560
	AATGACCGAA AGAATAAGAG CAGGCAAGCT ATTTACCGAT ATGTGCGAAG GCTTACCGGA	4620
	AAAAAGACTT CGTGGGAAAA CGTTAATGTA TGAGTTTAAT CACTCGCATC CATCAGAAGT	4680
	TGAAAAAGA GAAAGCCTGA TTAAAGAAAT GTTTGCCACG GTAGGGGAAA ACGCCTGGGT	4740
35	AGAACCGCCT GTCTATTTCT CTTACGGTTC CAACATCCAT ATAGGCCGCA ATTTTATGC	4800
	AAATTTCAAT TTAACCATG TCGATGACTA CACGGTAACA ATCGGTGATA ACGTACTGAT	4860
	TGCACCCAAC GTTACTCTTT CCGTTACGGG ACACCCTGTA CACCATGAAT TGAGAAAAA	4920
	CGGCGAGATG TACTCTTTTC CGATAACGAT TGGCAATAAC GTCTGGATCG GAAGTCATGT	4980



5	GGTTATTAAT CCAGGCGTCA CCATCGGGGA TAATTCTGTT ATTGGCGCGG GTAGTATCGT	5040
	CACAAAAGAC ATTCCACCAA ACGTCGTGGC GGCTGGCGTT CCTTGTCGGG TTATTCGCGA	5100
	AATAAACGAC CGGGATAAGC ACTATTATTT CAAAGATTAT AAAGTTGAAT CGTCAGTTTA	5160
	AATTATAAAA ATTGCCCTGAT ACGCTGCGCT TATCAGGCCT ACAAGTTCAG CGATCTACAT	5220
	TAGCCGCATC CGGCATGAAC AAAGCGCAGG AACAAGCGTC GCATCATGCC TCTTTGACCC	5280
10	ACAGCTGCGG AAAACGTACT GGTGCAAAAC GCAGGGTTAT GATCATCAGC CCAACGACGC	5340
	ACAGCGCATG AAATGCCCAG TCCATCAGGT AATTGCCGCT GATACTACGC AGCAGCCAG	5400
	AAAACCACGG GGCAAGCCCG GCGATGATAA AACCGATTCC CTGCATAAAC GCCACCAGCT	5460
	TGCCAGCAAT AGCCGGTTGC ACAGAGTGAT CGAGCGCCAG CAGCAAACAG AGCGGAAACG	5520
	CGCCGCCCAG ACCTAACCCA CACACCATCG CCCACAATAC CGGCAATTGC ATCGGCAGCC	5580
15	AGATAAAGCC GCAGAACCCC ACCAGTTGTA ACACCAGCGC CAGCATTAAAC AGTTTGCGCC	5640
	GATCCTGATG GCGAGCCATA GCAGGCATCA GCAAAGCTCC TGCGGCTTGC CCAAGCGTCA	5700
	TCAATGCCAG TAAGGAACCG CTGTACTGCG CGCTGGCACC AATCTCAATA TAGAAAGCGG	5760
	GTAACCAGGC AATCAGGCTG GCGTAACCGC CGTTAATCAG ACCGAAGTAA ACACCCAGCG	5820
	TCCACGCGCG GGGAGTGAAT ACCACGCGAA CCGGAGTGGT TGTGTCTTG TGGGAAGAGG	5880
20	CGACCTCGCG GCGCTTTGC CACCACCAGG CAAAGAGCGC AACAACGGCA GGCAGCGCCA	5940
	CCAGGCGAGT GTTTGATACC AGGTTTCGCT ATGTTGAACT AACCAGGGCG TTATGGCGGC	6000
	ACCAAGCCCA CCGCCGCCCA TCAGAGCCGC GGACCACAGC CCCATCACCA GTGGCGTGCG	6060
	CTGCTGAAAC CGCCGTTTAA TCACCGAAGC ATCACC GCCT GAATGATGCC GATCCCCACC	6120
	CCACCAAGCA GTGCGCTGCT AAGCAGCAGC GCACTTTGCG GGTAAAGCTC ACGCATCAAT	6180
25	GCACCGACGG CAATCAGCAA CAGACTGATG GCGACACTGC GACGTTTCGCT GACATGCTGA	6240
	TGAAGCCAGC TTCCGGCCAG CGCCAGCCCG CCCATGGTAA CCACCGGCAG AGCGGTCGAC	6300
	CCGGACGGGA CGCTCCTGCG CCTGATACAG AACGAATTGC TTGCAGGCAT CTCATGAGTG	6360
	TGTCTTCCCG TTTTCCGCCT GAGGTCACTG CGTGGATGGA GCGCTGGCGC CTGCTGCGCG	6420
	ACGGCGAGCT GCTCACCACC CACTCGAGCT GGATACTTCC CGTCCGCCAG GGGGACATGC	6480
30	CGGCGATGCT GAAGGTCGCG CGCATTCCTG ATGAAGAGGC CGGTTACCGC CTGTTGACCT	6540
	GGTGGGACGG GCAGGGCGCC GCCCGAGTCT TCGCCTCGGC GGCGGGCGCT CTGCTCATGG	6600
	AGCGCGCGTC CGGGGCCCGG GACCTTGACAC AGATAGCGTG GTCCGGCCAG GACGACGAGG	6660
	CTTGCAGGAT CTATGATTCC CTTTGTCAAC AGCAATGGAT CACTGAAAAT GGTTCATGA	6720
	TCACATTAAG TGGTATTCAA TATTTTCATG AAATGGGAAT TGACGTTTCT TCCAAACATT	6780
35	CACGTAAAAT CTGTTGTGCG TGTTTAGATT GGAGTGAACG CCGTTTCCAT TTAGGTGGGT	6840
	ACGTTGGAGC CGCATTATTT TCGCTTTATG AATCTAAAGG GTGGTTAACT CGACATCTTG	6900
	GTTACCGTGA AGTTACCATC ACGGAAAAAG GTTATGCTGC TTTTAAGACC CACTTTCACA	6960
	TTTAAGTTGT TTTTCTAATC CGCATATGAT CAATTCAAGG CCGAATAAGA AGGCTGGCTC	7020

5	TGCACCTTGG	TGATCAAATA	ATTCGATAGC	TTGTCGTAAT	AATGGCGGCA	TACTATCAGT	7080
	AGTAGGTGTT	TCCCTTTCTT	CTTTAGCGAC	TTGATGCTCT	TGATCTTCCA	ATACGCAACC	7140
	TAAAGTAAAA	TGCCCCACAG	CGCTGAGTGC	ATATAATGCA	TTCTCTAGTG	AAAAACCTTG	7200
	TTGGCATAAA	AAGGCTAATT	GATTTTTCGAG	AGTTTCATAC	TGTTTTTCTG	TAGGCCGTGT	7260
	ACCTAAATGT	ACTTTTGCTC	CATCGCGATG	ACTTAGTAAA	GCACATCTAA	AACTTTTAGC	7320
10	GTTATTACGT	AAAAAATCTT	GCCAGCTTTC	CCCTTCTAAA	GGGCAAAAGT	GAGTATGGTG	7380
	CCTATCTAAC	ATCTCAATGG	CTAAGGCGTC	GAGCAAAGCC	CGCTTATTTT	TTACATGCCA	7440
	ATACAATGTA	GGCTGCTCTA	CACCTAGCTT	CTGGGCGAGT	TTACGGGTTG	TTAAACCTTC	7500
	GATTCCGACC	TCATTAAGCA	GCTCTAATGC	GCTGTTAATC	ACTTTACTTT	TATCTAATCT	7560
	AGACATCATT	AATTCCTAAT	TTTTGTTGAC	ACTCTATCAT	TGATAGAGTT	ATTTTACCAC	7620
15	TCCCTATCAG	TGATAGAGAA	AAGTGAAATG	AATAGTTCGA	CAAAGATCGC	ATTGGTAATT	7680
	ACGTTACTCG	ATGCCATGGG	GATTGGCCTT	ATCATGCCAG	TCTTGCCAAC	GTTATTACGT	7740
	GAATTTATTG	CTTCGGAAGA	TATCGCTAAC	CACTTTGGCG	TATTGCTTGC	ACTTTATGCG	7800
	TTAATGCAGG	TTATCTTTGC	TCCTTGCTT	GGAAAAATGT	CTGACCGATT	TGGTCGGCGC	7860
	CCAGTGCTGT	TGTTGTCATT	AATAGGCGCA	TCGCTGGATT	ACTTATTGCT	GGCTTTTTCA	7920
20	AGTGCGCTTT	GGATGCTGTA	TTTAGGCCGT	TTGCTTTCAG	GGATCACAGG	AGCTACTGGG	7980
	GCTGTCGCGG	CATCGGTCAT	TGCCGATACC	ACCTCAGCTT	CTCAACGCGT	GAAGTGGTTC	8040
	GGTTGGTTAG	GGGCAAGTTT	TGGGCTTGGT	TTAATAGCGG	GGCCTATTAT	TGGTGGTTTT	8100
	GCAGGAGAGA	TTTCACCGCA	TAGTCCCTTT	TTTATCGCTG	CGTTGCTAAA	TATTGTCACT	8160
	TTCCTTGTTG	TTATGTTTTG	GTTCCGTGAA	ACCAAAAATA	CACGTGATAA	TACAGATACC	8220
25	GAAGTAGGGG	TTGAGACGCA	ATCGAATTCG	GTATACATCA	CTTTATTATA	AACGATGCCC	8280
	ATTTTGTTGA	TTATTTATTT	TTCAGCGCAA	TTGATAGGCC	AAATCCCCGC	AACGGTGTGG	8340
	GTGCTATTTA	CCGAAAATCG	TTTTGGATGG	AATAGCATGA	TGGTTGGCTT	TTCATTAGCG	8400
	GGTCTTGGTC	TTTTTACACTC	AGTATTCCAA	GCCTTTGTGG	CAGGAAGAAT	AGCCACTAAA	8460
	TGGGGCGAAA	AAACGGCAGT	ACTGCTCGAA	TTTATTGCAG	ATAGTAGTGC	ATTTGCCTTT	8520
30	TTAGCGTTTA	TATCTGAAGG	TTGGTTAGAT	TTCCCTGTTT	TAATTTTATT	GGCTGGTGGT	8580
	GGGATCGCTT	TACCTGCATT	ACAGGGAGTG	ATGTCTATCC	AAACAAAGAG	TCATGAGCAA	8640
	GGTGCTTTAC	AGGGATTATT	GGTGAGCCTT	ACCAATGCAA	CCGGTGTTAT	TGGCCCATTA	8700
	CTGTTTACTG	TTATTTATAA	TCATTCACTA	CCAATTTGGG	ATGGCTGGAT	TTGGATTATT	8760
	GGTTTAGCGT	TTTACTGTAT	TATTATCCTG	CTATCGATGA	CCTTCATGTT	AACCCCTCAA	8820
35	GCTCAGGGGA	GTAACAGGA	GACAAAGTGT	TAGTTATTTT	GTCACCAAAT	GATGTTATTC	8880
	CGCGAAATAT	AATGACCCTC	TTGATAACCC	AAGAGGGCAT	TTTTTACGAT	AAAGAAGATT	8940
	TAGCTTCAAA	TAAAACCTAT	CTATTTTATT	TATCTTTCAA	GCTCAATAAA	AAGCCGCGGT	9000
	AAATAGCAAT	AAATTGGCCT	TTTTTATCGG	CAAGCTCTTT	TAGGTTTTTT	GCATGTATTG	9060

5	CGATATGCAT AAACCAGCCA TTGAGTAAGT TTTTAAGCAC ATCACTATCA TAAGCTTTAA	9120
	GTTGGTTCTC TTGGATCAAT TTGCTGACAA TGGCGTTTAC CTTACCAGTA ATGTATTCAA	9180
	GGCTAATTTT TTCAAGTTCA TTCCAACCAA TGATAGGCAT CACTTCTTGG ATAGGGATAA	9240
	GGTTTTTATT ATTATCAATA ATATAATCAA GATAATGTTC AAATATACTT TCTAAGGCAG	9300
	ACCAACCATT TGTTAAATCA GTTTTTGTGG TGATGTAGGC ATCAATCATA ATTAATTGCT	9360
10	GCTTATAACA GGCACAGAGT AATTGTTTTT TATTTTTTAAA GTGATGATAA AAGGCACCTT	9420
	TGGTCACCAA CGCTTTTCCC GAGATCCTCT GCGACACCGC CGCTCGTCTG CACGCGCCGC	9480
	GGTCCGGACC GCCGCCGAT CTCCATCCGC TACAGGAATG GTTCCAGCCG CTTTTCCGGT	9540
	TGGCCGCTGA GCACGCGGCA CTTGCGCCCG CCGCCAGCGT AGCGCGCCAA CTTCTGGCGG	9600
	CGCCGCGCGA GGTGTGCCCC CTCCACGGCG ACCTGCACCA CGAGAACGTG CTCGACTTCG	9660
15	GCGACCGCGG CTGGCTGGCC ATCGACCCGC ACGGACTGCT CGGCGAGCGC ACCTTCGACT	9720
	ATGCCAACAT CTTACGAAT CCCGATCTCA GCGACCCCGG TCGCCCGCTT GCGATCCTGC	9780
	CGGGCAGGCT GGAGGCTCGA CTCAGCATTG TGGTCGCGAC GACCGGGTTT GAGCCCGAAC	9840
	GGCTTCTTCG CTGGATCATT GCATGGACGG GCTTGTGCGC AGCCTGGTTC ATCGGCGACG	9900
	GCGACGGCGA GGGCGAGGGC GCTGCGATTG ATCTGGCCGT AAACGCCATG GCACGCCGGT	9960
20	TGCTTGACTA GCGCGGTCAC CGATCTCACC TGGTCGTGCA GCTAGGTCAG GCCGTGTCGG	10020
	GCGTGATCCG CTGGAAGTCG TTGCGGGCCA CACCCGCCGC CTCGAAGCCC TGCACCAGGC	10080
	CGGCATCGTG GTGTGCGTGG CCGAGGGACT ATGGAAGGTG CCGGACGATC TGCCCGAGCA	10140
	GGGCCGCCGC TATGACGCCC AGCGTCTTGG TGGCGTGACG GTGGAGCTGA AATCGCACCT	10200
	GCCCATCGAG CGGCAGGCCC GCGTGATCGG TGCCACCTGG CTTGACCAGC AGTTGATCGA	10260
25	CGGTGGCTCG GGCTTGGGCG ACCTGGGCTT TAGCAGTGAG GCCAAGTAGG CGATACAGCA	10320
	GCGCGCGGAC TTCCTGGCCG AACAGGGACT GGCCGAGCGG CGCGGGCAGC GCGTGATCCT	10380
	CACCGGAATC TGCTGGGCAG CAGCGGGCTC GGGAACTGGC GCAGGCCGCG AAGGACATTG	10440
	CCGCCGATAC CGGCCTGGAG CATCGCCCCG TGGCCGACGG CCAGCGCGTT GCCGGCGTCT	10500
	ACCGGCGCCC CGTCATGCTC GCCAGCGGGC GAAATGGGAT GCTTGATGAC GCCAAGGGGT	10560
30	CCAGCCTCGT GCGGTGGAAG CCCATCGAAC AGCGGCTTGG GGAGCAGCTC GCCGCGACGG	10620
	TGCGCGGTGG CGGCGTGTCT TGGGAGATTG GACGACAGCG TGGGCCGGCC CCTGTCTCTT	10680
	GATCAGATCT TGATCCCCTG CGCCATCAGA TCCTTGGCGG CAAGAAAGCC ATCCAGTTTA	10740
	CTTTGCAGGG CTTCCCAACC TTCCCAGAGG GCGCCCCAGC TGGCAATTCC GGTTGCTTGG	10800
	CTGTCCATAA AACCGCCCAG TCTAGCTATC GCCATGTAAG CCCACTGCAA GCTACCTGCT	10860
35	TTCTCTTTGC GCTTGCGTTT TCCCTTGTCC AGATAGCCCA GTAGCTGACA TTCATCCGGG	10920
	GTCAGCACCG TTTCTGCGGA CTGGCTTTCT ACGTGTTCG CTTCTTTTAG CAGCCCTTGC	10980
	GCCCTGAGTG CTTGCGGCAG CGTGAAGCTT TCTCTGAGCT GTAACAGCCT GACCGCAACA	11040
	AACGAGAGGA TCGAGACCAT CCGCTCCAGA TTATCCGGCT CCTCCATGCG TTGCCTCTCG	11100

5	GCTCCTGCTC CGGTTTTCCA TGCCTTATGG AACTCCTCGA TCCGCCAGCG ATGGGTATAA	11160
	ATGTCGATGA CGCGCAAGGC TTGGGCTAGC GACTCGACCG GTTCGCCGGT CAGCAACAAC	11220
	CATTTCAACG GGGTCTCACC CTTGGGCGGG TTAATCTCCT CGGCCAGCAC CGCGTTGAGC	11280
	GTGATATTCC CCTGTTTTAG CGTGATGCGC CCACTGCGCA GGCTCAAGCT CGCCTTGCGG	11340
	GCTGGTCGAT TTTTACGTTT ACCGCGTTTA TCCACCACGC CCTTTTGCGG AATGCTGATC	11400
10	TGATAGCCAC CCAACTCCGG TTGGTTCTTC AGATGGTCGA TCAGATACAA CCCAGACTCT	11460
	ACGTCCTTGC GTGGGTGCTT GGAGCGCACC ACGAAGCGCT CGTTATGCGC CAGCCTGTCC	11520
	TGCAGATAAG CATGAATATC GGCTTCGCGG TCACAGACCG CAATCACGTT GCTCATCATG	11580
	CTGCCCATGC GTAACCGGCT AGTTGCGGCC GCTGCCAGCC ATTTGCCACT CTCCTTTTCA	11640
	TCCGCATCGG CAGGGTCATC CGGGCGCATC CACCACTCCT GATGCAGTAA TCCTACGGTG	11700
15	CGGAATGTGG TGGCCTCGAG CAAGAGAACG GAGTGAACCC ACCATCCGCG GGATTTATCC	11760
	TGAATAGAGC CCAGCTTGCC AAGCTCTTCG GCGACCTGGT GGCGATAACT CAAAGAGGTG	11820
	GTGTCCTCAA TGGCCAGCAG TTCGGGAAAC TCCTGAGCCA ACTTGACTGT TTGCATGGCG	11880
	CCAGCCTTTC TGATCGCCTC GGCAGAAACG TTGGGATTGC GGATAAATCG GTAAGCGCCT	11940
	TCCTGCATGG CTTCACTACC CTCTGATGAG ATGGTTATTG ATTTACCAGA ATATTTTGCC	12000
20	AATTGGGCGG CGACGTTAAC CAAGCGGGCA GTACGGCGAG GATCACCAG CGCCGCCGAA	12060
	GAGAACACAG ATTTAGCCCA GTCGGCCGCA CGATGAAGAG CAGAAGTTAT CATGAACGTT	12120
	ACCATGTTAG GAGGTCACAT GGAAGATCAG ATCCTGGAAA ACGGGAAAGG TTCCGTTCTGA	12180
	ATTGCATGCG GATCCGGGAT CAAGATCTGA TCAAGAGACA GGTACCAATT GTTGAAGACG	12240
	AAAGGGCCTC GTGATACGCC TATTTTTATA GGTTAATGTC ATGATAATAA TGTTTTCTTA	12300
25	GACGTCAGGT GGCACCTTTC GGGGAAATGT GCGCGGAACC CCTATTGTGTT TATTTTTCTA	12360
	AATACATTCA AATATGTATC CGCTCATGAG ACAATAACCC TGATAAATGC TTCAATAATA	12420
	TTGAAAAAGG AAGAGTATGA GTATTCAACA TTTCCGTGTC GCCCTTATTC CCTTTTTTGC	12480
	GGCATTTTGC CTTCTGTTT TTGCTCACCC AGAAACGCTG GTGAAAGTAA AAGATGCTGA	12540
	AGATCAGTTG GGTGCACGAG TGGGTTACAT CGAACTGGAT CTCAACAGCG GTAAGATCCT	12600
30	TGAGAGTTTT CGCCCCGAAG AACGTTTTCC AATGATGAGC ACTTTTAAAG TTCTGCTATG	12660
	TGGCGCGGTA TTATCCCGTG TTGACGCCGG GCAAGAGCAA CTCGGTCGCC GCATACACTA	12720
	TTCTCAGAAT GACTTGTTG AGTACTTGGC AAACGTGATCT AAATGTTTAG CCCAGTCATC	12780
	ATACTTCACC GATGCCAACG CATTAAAAAT AGCATCACGA TCGGCTTTGC TGAATTTCTT	12840
	ATTTAAAACA TCCTTGTAAT TTTCAAAAGC AGCGAGAGCT TCATTACAT TGCCGATTTT	12900
35	CTTACCTTTA GACTTATCAG CAAGTTCCTG TGCCATTTTC GAATATTTTT CACCATATTT	12960
	TTCAGTCAGC GTTTGATAAA AGCTAACTGT TGCATCAACA GCATCCTTAA TCTGTGAATT	13020
	AAGGAGATTA TTCTGTGCTT TTTTCAAATT TTCTTCAGCT TCATGAACAC GAGCGATACC	13080
	GGCATTACGA TTATTACTGA CCTGAGAAAT AGCCTTCTGG ATCTGAGTTA TATCAGCATT	13140

5	TATCCGGTTA ATACGTGTTT CTGATGCTGT TACCTGTTTT TGTTTTCTT CTCTAATCTT	13200
	ACCGGCCCCA ACCCGTCGTC TGGTTGCTTC AAAAAAAGGA CGGTTCTGAA GCGGATCATT	13260
	GGCTCTTGGT GATAGTTTTT TGACCAGCTC ATCCAGTTCT TTATATTTAG CGGATGCCTG	13320
	AGCCAGTTCA TTTCGTTTTT CAGCGAGCGT TTTCATTTCT GCATCACGGG CATGGATACT	13380
	GGAGCTTAAA CGAGAATTGA GAGTCTTAAT CTCTCCATCC ATTTTCACCA CTTTCAGATTG	13440
10	TGCAGCAGAA AGTTTTTTTT GGGCGATCTC AACAGCTTTA GCTTCTTCAC TCAATGCAGC	13500
	CAGTCGTTTC TCTTCAGCTT CAGCCAGTTT CAACTGGCGT TCTGTTTCAG CCTTCTCCCG	13560
	TTCAATCTCT TTACGTCGTT GTTCTGCTTC CTGAAAAGCC TTTTCTGCTG CTTCCGCTTC	13620
	TTTACGGGCT TTTTCTTCTG CTTTCGCAAG GCGCAAACGC TCTGCTTCCG CCTGCATAGC	13680
	TGCATTATTA GCATGAGCAA GCTCTGTTGC TGAAGGCGTA CGTGAGGCAT TGTGACGAAG	13740
15	AGCCTCATTC ACGATATCCT TCAGGCGCTG AGTCAGCGCA TCCCTGTTTG CCTTGCTTT	13800
	CGCCTGTGCT TCCGCTGCAG CTTTTGCCCC GGCAGCCTGC TCTGCCTGTG TTTCTTTTAA	13860
	TTGAGCAGTA GACCATTTAG CAGTTGCATG AATAGCTGCA GAACTTTCAC TTTTACTGCC	13920
	TCCTTTTCCA CCTCCGCCGC CAGAGCCACT CCCGTCAGGA GTACCATTCA AAAGAGTAAT	13980
	AATTACCTGT CCCTTATCAT CATAAGGAAC ACCATCTTTA TAGTACGCTA CCGCGGTTTC	14040
20	CATTATAAAA TCCTCTTTGA CTTTTTAAAC AATAAGTTAA AAATAAATAC TGTACATATA	14100
	ACCACTGGTT TTATATACAG CATAAAAGCT ACGCCGCTGC ATTTTCCCTG TCAAGACTGT	14160
	GGACTTCCAT TTTTGTGAAA ACGATCAAAA AAACAGTCTT TCACACCACG CGCTATTCTC	14220
	GCCCCGATGCC ACAAAAACCA GCACAAACAT TACCGTTCTC AGACCTCATT ATGTTTTACT	14280
	GAAACTATGA GATGAGACAT CTATGGGACA CTGTCACTTT ATGGCATGGC ACACACTCCG	14340
25	GGACGCACTA AAAATGACAG GCAGATCGCG TTCACAGTTT TACCGTGATA TGCGCGGAGG	14400
	CCTTGTCAGT TACCGTACCG GCAGGGACGG ACGACGGGAG TTTGAAACCA GTGAACTGAT	14460
	CCGGGCATAC GGCGAATTAA AGCAGAATGA GACACCAGAA AGGCACAGTG AGGGACATGC	14520
	AGAAAATCCA CATGATCAGC AGACAGAACG CATTCTCCGG GAACTGAATG AGCTGAAACA	14580
	ATGCCTGACG CTGATGCTTG AGGATAAACA GGCACAGGAT ATGGATCGCA GACGCCAGGA	14640
30	AGCAGAACGG GAACAGCTAC AAAATGAGAT AGCCCAGCTC AGGCAGGCAC TGGAAGTGGG	14700
	AAAGAAACGG GGATTCTGGT CCAGGTTGTT CGGTCGCTGA ACGCTGTCAG AGACTGATGA	14760
	TAAAATAGTC TTCGGATAAT AACTCACCGA GAATAAATAC TTTAAGGTAG GGAGACACTC	14820
	ATGAGACGTA CCGGAAACAA ACTTTGTCTT ATCGCCATGA TAACAGCAAC AGTAGCTCTC	14880
	ACAGCCTGTA CCCCAGGG CAGCGTGGAA CAACATACCC GGCATTACGT ATATGCTTCT	14940
35	GATGACGTTT TTGATCCCAA CTTTTCCACC CAAAAGCCG ACACAACACG AATGATGGTG	15000
	CCTTTTTTTC GGCAGTTCTG GGATATGGGA GCTAAAGACA AAGCGACAGG AAAATCACGG	15060
	AGTGATGTGC AACAACGCAT TCAGCAGTTT CACAGCCAAG AATTTTAAA CTCACTCCGG	15120
	GGCACAACCTC AATTGCGGG TACTGATTAC CGCAGCAAAG ACCTTACCCC GAAAAAATCC	15180

5	AGGCTGCTGG CTGACACGAT TTCTGCGGTT TATCTCGATG GCTACGAGGG CAGACAGTAA	15240
	GTGGATTTAC CATAATCCCT TAATTGTACG CACCGCTAAA ACGCGTTCAG CGCGATCACG	15300
	GCAGCAGACA GGTA AAAATG GCAACAAACC ACCCTAAAAA CTGCGCGATC GCGCCTGATA	15360
	AATTTTAACC GTATGAATAC CTATGCAACC AGAGGGTACA GGCCACATTA CCCCCACTTA	15420
	ATCCACTGAA GCTGCCATTT TTCATGGTTT CACCATCCCA GCGAAGGGCC ATCCAGCGTG	15480
10	CGTTCCTGTA TTTCCGGCTG ACGCTCCCGT TCTAGGGATA ACACATGTTC GCGCTCCTGT	15540
	ATCAGCCGTT CCTCTCTTAT CTCCAGTTCT CGCTGTATAA CTGGCTCAAG CGTTCTGTCT	15600
	GCTCGCTCAA GTGTTGCACC TGCTGACTCA ACTGCATGAC CCGCTCGTTC AGCATCGCGT	15660
	TGTCCCGTTG CGTAAGCGAA AACATCTTCT GCAATTCCAC GAAGGCGCTC TCCCATTGCG	15720
	TCAGCCGCTG CATATAGTCC TGTTGCAGCT GCTCTAAGGC GTTCAGCAA TGTGTTTCCA	15780
15	GCTCTGTCAC TCTGTGTCAC TCCTTCAGAT GTACCCACTC TTTCCCCTGA AAGGGAATCA	15840
	CCTCCGCTGA TTTCCCGTAC GGAAGGACAA GGAATTTCTT GTTCCCGTCC TGCACAAACT	15900
	CCACGCCCCA TGTCTTCGCG TTCAGTTTCT GCAATGTCTC TTCCTGCTTC CTGATTTCTT	15960
	CCAGGTTGCG CTGTATCCTC CCTCCAAGAT ACCAGAGCGT CCCGCCACTC GCGGTAAACA	16020
	GGAGAAAGAC TATCCCCAGT AACATCATGC CCGTATTCCC TGCCAGCTTT AACACGTCCC	16080
20	TCCTGTGCTG CATCATCGCC TCTTTCACCC CTTCCCGGTG TTTTTCAGC GATTCCTCTG	16140
	TCGAGGCTGT GAACAGGGCT ATAGCGTCTC TGATTTTCGT CTCGTTTGAT GTCACAGCCT	16200
	CGCTTACAGA TTCGCCGAGC CTCCTGAACT CGTTGTTTCT CATTCTCTCT GTAGATTCGG	16260
	CTCTCTCTTT CAGCTTTTTT TCGAACTCCG CGCCCGTCTG CAAAAGATTG CTCATAAAAT	16320
	GTCCTTTTCA GCCTGATATT CTTCCCGCCG TTCGGATCTG CAATGCTGAT ACTGCTTCGC	16380
25	GTCACCCTGA CCACTTCCAG CCCCCTCA GTGAGCGCCT GAATCACATC CTGACGGCCT	16440
	TTTATCTCTC CGGCATGGTA AAGTGCATCT ATACCTCGCG TGACGCCCTC AGCAAGCGCC	16500
	TGTTTCGTTT CAGGCAGGTT ATCAGGGAGT GTCAGCGTCC TGCGGTTCTC CGGGGCGTTC	16560
	GGGTCA TGCA GCCCGTAATG GTGATTTAAC AGCGTCTGCC AAGCATCAAT TCTAGGCCTG	16620
	TCTGCGCGGT CGTAGTACGG CTGGAGGCGT TTTCCGGTCT GTAGCTCCAT GTTCGGAATG	16680
30	ACAAAATTCA GCTCAAGCCG TCCCTTGTCC TGGTGCTCCA CCCACAGGAT GCTGTACTGA	16740
	TTTTTTTCGA GACCGGGCAT CAGTACACGC TCAAAGCTCG CCATCACTTT TTCACGTCCT	16800
	CCCGGCGGCA GCTCCTTCTC CGCGAACGAC AGAACACCGG ACGTGTATTT CTTGCGAAAT	16860
	GGCGTGGCAT CGATGAGTTC CCGGACTTCT TCCGGTATAC CCTGAAGCAC CGTTGCGCCT	16920
	TCGCGGTTAC GCTCCCTCCC CAGCAGGTAA TCAACCGGAC CACTGCCACC ACCTTTTCCC	16980
35	CTGGCATGAA ATTTAACTAT CATCCCGCGC CCCCTGTTCC CTGACAGCCA GACGCAGCCG	17040
	GCGCAGCTCA TCCCCGATGG CCATCAGTGC GGCCACCACC TGAACCCGGT CACCGGAAGA	17100
	CCACTGCCCC CTGTTACCT TACGGGCTGT CTGATTCAGG TTATTTCCGA TGGCGGCCAG	17160
	CTGACGCAGT AACGGCGGTG CCAGTGTCGG CAGTTTTCG GAACGGGCAA CCGGCTCCCC	17220

5	CAGGCAGACC CGCCGCATCC ATACCGCCAG TTGTTTACCC TCACAGCGTT CAAGTAACCG	17280
	GGCATGTTCA TCATCAGTAA CCCGTATTGT GAGCATCCTC TCGCGTTTCA TCGGTATCAT	17340
	TACCCCATGA ACAGAAATCC CCCTTACACG GAGGCATCAG TGAATAACA GGAAAAAACC	17400
	GCCCTTAACA TGGCCCGCTT TATCAGAAGC CAGACATTAA CGCTGCTGGA GAAGCTCAAC	17460
	GAACTGGACG CAGATGAACA GGCCGATATT TGTGAATCGC TTCACGACCA CGCCGATGAG	17520
10	CTTTACCGCA GCTGCCTCGC ACGTTTCGGG GATGACGGTG AAAACCTCTG ACACATGCAG	17580
	CTCCCGGAGA CGGTCACAGC TTGTCTGTGA GCGGATGCCG GGAGCTGACA AGCCCGTCAG	17640
	GGCGCGTCAG CAGGTTTTAG CGGGTGTCGG GCGCGAGCCC TGACCCAGTC ACGTAGCGAT	17700
	AGCGGAGTGT ATACTGGCTT AACCATGCGG CATCAGTGCG GATTGTATGA AAAGTACGCC	17760
	ATGCCGGGTG TGAAATGCCG CACAGATGCG TAAGGAGAAA ATGCACGTCC AGGCGCTTTT	17820
15	CCGCTTCCTC GCTCACTGAC TCGCTACGCT CGGTCGTTTCG ACTGCGGCGA GCGGTACTGA	17880
	CTCACACAAA AACGGTAACA CAGTTATCCA CAGAATCAGG GGATAAGGCC GGAAAGAACA	17940
	TGTGAGCAAA AGACCAGGAA CAGGAAGAAG GCCACGTAGC AGGCGTTTTT CCATAGGCTC	18000
	CGCCCCCTG ACGAGCATCA CAAAAATAGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA	18060
	GGACTATAAA GCTACCAGGC GTTTCCTCCCT GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG	18120
20	ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT	18180
	CATAGCTCAC GCTGTTGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT	18240
	GTGCACGAAC CCCCCGTTCA GCCCCACCGC TCGCCTTAT CCGGTAAC TAAGTCTTGAG	18300
	TCCAACCCGG TAAGGCACGC CTTAACGCCA CTGGCAGCAG CCACTGGTAA CCGGATTAGC	18360
	AGAGCGATGA TGGCACAAAC GGTGCTACAG AGTTCTTGAA GTAGTGGCCC GACTACGGCT	18420
25	AACTAGAAAG GACAGTATTT GGTATCTGCG CTCTGCTGAA GCCAGTTACC TTCGGAAAAA	18480
	GAGTTGGTAG CTCTTGATCC GGCAACAAA CCACCGTTGG TAGCGGTGGT TTTTGTGTTT	18540
	GCAAGCAGCA GATTACGCGC AGAAAAAAG GATCTCAAGA AGATCCTTTA ATCTTTTCTA	18600
	CTGAACCGCG ATCCCCGTCA GTTTAGAAGA GGAGGATGGT GCGATGGTCC CTCCCTGAAC	18660
	ATCAGGTATA TAGTTAGCCT GACATCCAAC AAGGAGGTTT ATCGCGAATA TTCCACAAA	18720
30	AAATCTTTTC CTCATAACTC GATCCTTATA AATGAAAAG AATATATGGC GAGGTTTAAT	18780
	TTATGAGCTT AAGATACTAC ATAAAAATA TTTTATTTGG CCTGTACTGC AACTTATAT	18840
	ATATATACCT TATAACAAA AACAGCGAAG GGTATTATTT CTTGTGTCA GATAAGATGC	18900
	TATATGCAAT AGTGATAAGC ACTATTCTAT GTCCATATTC AAAATATGCT ATTGAATACA	18960
	TAGCTTTTAA CTTATAAAG AAAGATTTTT TCGAAAGAAG AAAAAACCTA AATAACGCCC	19020
35	CCGTAGCAAA ATTAAACCTA TTTATGCTAT ATAATCTACT TTGTTTGGTC CTAGCAATCC	19080
	CATTTGGATT GCTAGGACTT TTTATATCAA TAAAGAATAA TTAAATCCCT AACACCTCAT	19140
	TTATAGTATT AAGTTTATTC TTATCAATAT AGGAGCATAG AA	19182

1. A system for transposing a transposable DNA sequence *in vitro*, the system comprising:

a Tn5 transposase modified relative to a wild type Tn5 transposase, the modified transposase comprising a change relative to the wild type Tn5 transposase that causes the modified transposase to bind to Tn5 outside end repeat sequences with greater avidity than the wild type Tn5 transposase, and a change relative to the wild type Tn5 transposase that causes the modified transposase to be less likely than the wild type transposase to assume an inactive multimeric form;

a donor DNA molecule comprising the transposable DNA sequence, the DNA sequence being flanked at its 5'- and 3'-ends by the Tn5 outside end repeat sequences; and

a target DNA molecule into which the transposable element can transpose.

2. A system as claimed in Claim 1 wherein the change that causes the modified transposase to bind with greater avidity is characterized as a substitution mutation at position 54 of the wild type transposase.

3. A system as claimed in Claim 2 wherein position 54 is a lysine.

4. A system as claimed in Claim 1 wherein the change that causes the modified transposase to be less likely to assume an inactive multimeric form is characterized as a substitution mutation at position 372 of the wild type transposase.

5. A system as claimed in Claim 4 wherein position 372 is a proline.

6. A system as claimed in Claim 1 wherein the modified transposase further comprises a substitution mutation at position 56 of the wild type transposase.



7. A system as claimed in Claim 6 wherein position 56 is an alanine.

8. A system as claimed in Claim 1 wherein the donor DNA molecule is flanked at its 5'- and 3'-ends by an 18 or 19 base pair flanking DNA sequence comprising nucleotide A at position 10, nucleotide T at position 11, and nucleotide A at position 12.

9. The system as claimed in Claim 8 wherein the flanking sequence further comprises a nucleotide at position 4 selected from the group consisting of A or T.

10. The system as claimed in Claim 8 wherein the flanking sequence further comprises a nucleotide at position 15 selected from the group consisting of G or C.

11. The system as claimed in Claim 8 wherein the flanking sequence further comprises a nucleotide at position 17 selected from the group consisting of A or T.

12. The system as claimed in Claim 8 wherein the flanking sequence further comprises a nucleotide at position 18 selected from the group consisting of G or C.

13. The system as claimed in Claim 8 wherein the flanking sequence has the sequence 5'-CTGTCTCTTATACACATCT-3'.

14. The system as claimed in Claim 8 wherein the flanking sequence has the sequence 5'-CTGTCTCTTATACAGATCT-3'.

15. A Tn5 transposase modified relative to a wild type Tn5 transposase, the modified transposase comprising:

a change relative to the wild type Tn5 transposase that causes the modified transposase to bind to Tn5 outside end repeat sequences of a donor DNA with greater avidity than the wild type Tn5 transposase; and

a change relative to the wild type Tn5 transposase that causes the modified transposase to be less likely than the wild type transposase to assume an inactive multimeric form.

16. A modified Tn5 transposase as claimed in Claim 15 wherein the change that causes the modified transposase to bind with greater avidity is characterized as a substitution mutation at position 54 of the wild type transposase.

17. A modified Tn5 transposase as claimed in Claim 16 wherein position 54 is a lysine.

18. A modified Tn5 transposase as claimed in Claim 15 wherein the change that causes the modified transposase to be less likely to assume an inactive multimeric form is characterized as a substitution mutation at position 372 of the wild type transposase.

19. A modified Tn5 transposase as claimed in Claim 18 wherein position 372 is a proline.

20. A modified Tn5 transposase as claimed in Claim 15 further comprising a substitution mutation at position 56 of the wild type transposase.

21. A modified Tn5 transposase as claimed in Claim 20 wherein position 56 is alanine.

22. A genetic construct comprising a nucleotide sequence that can encode a Tn5 transposase that both has greater avidity for Tn5 outside end repeats and is less likely to assume an inactive multimeric form than a wild type Tn5 transposase.

23. A genetic construct as claimed in Claim 22 comprising a nucleotide sequence that encodes a lysine residue at amino acid 54 of the transposase.

24. A genetic construct as claimed in Claim 22 comprising a nucleotide sequence that encodes a proline residue at amino acid 372 of the transposase.

25. A genetic construct as claimed in Claim 22 comprising a nucleotide sequence that encodes a lysine residue at amino acid 54 of the transposase and a proline residue at amino acid 372 of the transposase.

26. A genetic construct as claimed in Claim 22 comprising the nucleotide sequence of SEQ ID NO:1.

27. A genetic construct comprising:  
a transposable DNA sequence flanked at its 5' and 3' ends by an 18 or 19 base pair flanking DNA sequence comprising nucleotide A at position 10, nucleotide T at position 11, and nucleotide A at position 12.

28. The construct of Claim 27 further comprising, at position 4 of the flanking sequence, a nucleotide selected from the group consisting of T or A.

29. The construct of Claim 27 further comprising, at position 15 of the flanking sequence, a nucleotide selected from the group consisting of G or C.

30. The construct of Claim 27 further comprising, at position 17 of the flanking sequence, a nucleotide selected from the group consisting of T or A.

31. The construct of Claim 27 further comprising, at position 18 of the flanking sequence, a nucleotide selected from the group consisting of G or C.

32. The construct as claimed in Claim 27 wherein the flanking sequence has the sequence 5'-CTGTCTCTTATACACATCT-3'.

33. The construct as claimed in Claim 27 wherein the flanking sequence has the sequence 5'-CTGTCTCTTATACAGATCT-3'.

34. A method for *in vitro* transposition, the method comprising the steps of:

combining a donor DNA molecule that comprises a transposable DNA sequence of interest, the DNA sequence of interest being flanked at its 5'- and 3'-ends by Tn5 outside end repeat sequences, with a target DNA molecule and a Tn5 transposase modified relative to wild type Tn5 transposase in a suitable reaction buffer at a temperature below a physiological temperature until the modified transposase binds to the outside end repeat sequences; and

raising the temperature to a physiological temperature for a period of time sufficient for the enzyme to catalyze *in vitro* transposition,

wherein the modified transposase comprises a change relative to the wild type Tn5 transposase that causes the modified transposase to bind to the Tn5 outside end repeat sequences with greater avidity than the wild type Tn5 transposase, and a change relative to the wild type Tn5 transposase that causes the modified transposase to be less likely than the wild type transposase to assume an inactive multimeric form.

35. A method as claimed in Claim 34 wherein the change that causes the modified transposase to bind with greater avidity is characterized as a substitution mutation at position 54 of the wild type transposase.

36. A method as claimed in Claim 35 wherein position 54 is a lysine.

37. A method as claimed in Claim 34 wherein the change that causes the modified transposase to be less likely to assume an inactive multimeric form is characterized as a substitution mutation at position 372 of the wild type transposase.

38. A method as claimed in Claim 37 wherein position 372 is a proline.

39. A method as claimed in Claim 34 wherein the modified transposase further comprises a substitution mutation at position 56 of the wild type transposase.

40. A method as claimed in Claim 39 wherein position 56 is an alanine.

41. A method as claimed in Claim 34 wherein the DNA sequence of interest is flanked at its 5'- and 3'-ends by an 18 or 19 base pair flanking DNA sequence comprising nucleotide A at position 10, nucleotide T at position 11, and nucleotide A at position 12.

42. The method as claimed in Claim 41 wherein the flanking sequence further comprises a nucleotide at position 4 selected from the group consisting of A or T.

43. The method as claimed in Claim 41 wherein the flanking sequence further comprises a nucleotide at position 15 selected from the group consisting of G or C.

44. The method as claimed in Claim 41 wherein the flanking sequence further comprises a nucleotide at position 17 selected from the group consisting of A or T.

45. The method as claimed in Claim 41 wherein the flanking sequence further comprises a nucleotide at position 18 selected from the group consisting of G or C.

46. The method as claimed in Claim 41 wherein the flanking sequence has the sequence 5'-CTGTCTCTTATACACATCT-3'.

47. The method as claimed in Claim 41 wherein the flanking sequence has the sequence 5'-CTGTCTCTTATACAGATCT-3'.

1/8





FIG 1

**THIS PAGE BLANK (USPTO)**






no Tnp control  
 intra molecular-transformant  
 inter molecular-transformant  
 in vitro products circular substrate  
 in vitro products linear substrate  
 MW standards

**FIG 2**  
**SUBSTITUTE SHEET (RULE 26)**

**THIS PAGE BLANK (USPTO)**



**FIG 3**  
**SUBSTITUTE SHEET (RULE 26)**

**THIS PAGE BLANK (USPTO)**




FIG 4

**THIS PAGE BLANK (USPTO)**

5/8

a

## Papillation of IE Mutants with EK54 Tnp




FIG 5

**THIS PAGE BLANK (USPTO)**



b

## Papillation of IE Mutants with EK54 Tnp




FIG 6

**THIS PAGE BLANK (USPTO)**

## Papillation of IE Mutants with wt Tnp





FIG 7

**THIS PAGE BLANK (USPTO)**

8/8

**a****FIG 8**

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15941

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/55 C12N9/22 C12N15/90 C12N15/85

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

X

ZHOU M ET AL: "Three types of novel mutations in the NH-2-terminus of Tn5 transposase: Structure-function of transposase."  
KEYSTONE SYMPOSIUM ON TRANSPOSITION AND SITE-SPECIFIC RECOMBINATION: MECHANISM AND BIOLOGY, PARK CITY, UTAH, USA, JANUARY 21-28, 1994. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (18B). 1994. 45. ISSN: 0733-1959, XP002052633  
see the whole document  
---  
-/--

1-3,  
15-17,  
22,23,  
26,34-36

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

20 January 1998

Date of mailing of the international search report

03/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Hix, R

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15941

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WEINREICH M D ET AL: "Evidence that the cis preference of the Tn5 transposase is caused by nonproductive multimerization." GENES & DEVELOPMENT 8 (19). 1994. 2363-2374. ISSN: 0890-9369, XP002052634 cited in the application see the whole document	1,4,5, 15,18, 19,22, 24,26, 34,37,38
Y	DELONG, ALISON ET AL: "Trans-acting transposase mutant from Tn5" PROC. NATL. ACAD. SCI. U. S. A. (1991), 88(14), 6072-6 CODEN: PNASA6;ISSN: 0027-8424, 1991, XP002052635 see the whole document	1-47
Y	WIEGAND, TORSTEN W. ET AL: "Characterization of two hypertransposing Tn5 mutants" J. BACTERIOL. (1992), 174(4), 1229-39 CODEN: JOBAAY;ISSN: 0021-9193, February 1992, XP002052636 see the whole document	1-47
Y	WIEGAND, TORSTEN WALTER: "Transposase mutants that increase the transposition frequency of Tn5" (1993) 164 PP. AVAIL.: UNIV. MICROFILMS INT., ORDER NO. DA9315014 FROM: DISS. ABSTR. INT. B 1993, 54(6), 2886, 1993, XP002052637 see the whole document	1-47
Y	WEINREICH M D ET AL: "A functional analysis of the Tn5 transposase. Identification of domains required for DNA binding and multimerization." J. MOL. BIOL., vol. 241, 1993, pages 166-177, XP002052638 see the whole document	1-47
Y	JILK R A ET AL: "The organization of the outside end of transposon Tn5." JOURNAL OF BACTERIOLOGY, vol. 178, no. 6, March 1996, pages 1671-1679, XP002052640 see the whole document	1-47

-/--



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/15941

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	R.C. JOHNSON ET AL.: "DNA sequences at the ends of transposon Tn5 required for transposition." NATURE, vol. 304, 21 July 1983, pages 280-282, XP002052641 cited in the application see the whole document	1-47
P,Y	YORK, DONA ET AL: "Purification and biochemical analyses of a monomeric form of Tn5 transposase" NUCLEIC ACIDS RES. (1996), 24(19), 3790-3796 CODEN: NARHAD;ISSN: 0305-1048, 1996, XP002052642 see the whole document	1-47
P,X	ZHOU M ET AL: "Tn5 transposase mutants that alter DNA binding specificity." JOURNAL OF MOLECULAR BIOLOGY 271 (3). 1997. 362-373. ISSN: 0022-2836, XP002052643 see the whole document	1-47
P,X	YORK, DONA ET AL: "DNA binding and phasing analyses of Tn5 transposase and a monomeric variant" NUCLEIC ACIDS RES. (1997), 25(11), 2153-2160 CODEN: NARHAD;ISSN: 0305-1048, 1997, XP002052645 see the whole document	1-47

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**